Top

Guillermo Garcia-Manero, M.D.

Department of Leukemia, Division of Cancer Medicine

4.9/5

About Dr. Guillermo Garcia-Manero

For the last 25 years, Dr. Garcia-Manero's effort has focused on improving the outcomes and quality of life of patients with leukemia and in particular myelodysplastic syndromes. His work centers around the understanding of the pathophysiology of these disorders in an attempt to develop new therapeutic interventions. He currently leads the largest MDS program in the world and directs the MDS/AML Moon Shot^® program at MD Anderson. This work has resulted in over 1,000 publications in the areas of biology, therapy and prognostication of these disorders, and development of multiple therapeutic clinical trials.

Present Title & Affiliation

Primary Appointment

Fellowship Program Director, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas

Leader of the MDS/AML Moon Shot Program, The University of Texas MD Anderson Cancer Center, Houston, Texas

Deputy Chair, Translational Research, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor with Tenure, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate (without salary), Department of Graduate School of Biomedical Sciences Dean's Office, Graduate School of Biomedical Sciences, Houston, Texas

Education & Training

Board Certifications

Experience & Service

Academic Appointments

Associate Professor with Tenure, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2010

Assistant Professor, Department of Division of Oncology, The University of Texas Health Science Center at Houston, Houston, TX, 1999 - 2002

Assistant Professor, Tenure Track, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2005

Administrative Appointments/Responsibilities

Part Chair and Past Chair, Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - 2022

Chair, Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2021

Chair Elect, Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - 2020

Co-Director, Department of DNA Methylation Core, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2017

Chief Fellow, Department of Division of Hematology and Medical Oncology, Thomas Jefferson University, Philadelphia, PA, 1998 - 1999

Other Appointments/Responsibilities

Chair, MDS Clinical Research Consortium, Rockville, MD, 2017 - 2018

Advisory Board Member, Incyte Corporation, Dallas, Texas, 2016 - 2017

Start-Up Funds Proposal Review, UT MD Anderson Cancer Center, Houston, TX, 2016

Advisor to the Data Safety Monitoring Board, AstraZeneca Anifrolumab program, Gaithersburg, MD, 2015

Chair, MDS Clinical Research Consortium, Rockville, MD, 2015 - 2016

Independent Data Monitoring Committee Member, GlaxoSmithKline, Billerica, MA, 2013 - Present

Member, SWOG Leukemia Committee, Portland, OR, 2012 - 2015

Consultantships, MEI Pharma, Inc, San Diego, CA, 2012 - 2015

Chair, Independent Data Monitoring Committee, GlaxoSmithKline, London, 2011 - Present

Global MDS/AML Steering Committee, Celgene, Orlando, FL, 2010 - 2019

Consultantships, Celgene Corporation, Summit, NJ, 2007 - 2019

Consultantships, Novartis, East Hanover, NJ, 2007 - Present

Consultantships, Bristol-Myers Squibb, New York City, 2007 - Present

Consultantships, Merck & Co., Inc, Whitehouse Station, NJ, 2007 - Present

Member, Memorial Hermann Hospital, Cancer Committee, Houston, TX, 1999 - 2002

Member, American Association for the Advancement of Science, Houston, TX, 1999 - Present

Medical Corporal, Infantry Regiment "PALMA" 47, Spanish Armed Forces, 1992 - 1992

Emergency Room Physician, Omesa Medical Center, Palma de Mallorca, 1991 - 1992

Institutional Committee Activities

Member, DoCM Division Head Search Committee, 2022

Member, Institutional Conflict of Interest, 2021 - 2022

Member, HMB Chair Candidate Search Committee, 2021 - 2022

Member, UT System Faculty Advisory Council, 2020 - 2022

Member, EC Patient Flow, 2020 - 2022

Committee Member, COVID-19 Core Leadership Team, 2020 - 2022

Committee Member, Strategic Position Management Committee, 2020 - 2022

Committee Member, LeMaistre Award Committee, 2020 - 2022

Member, President's Advisory Council, 2019 - 2022

Member, Moon Shot FIT RFA Steering Committee, 2019 - 2022

Member, Clinical Research Billing Compliance Subcommittee, 2018 - 2022

Leader, ASCO Scientific Program Committee, 2018 - 2019

Member, Executive Committee of Faculty Senate, 2017 - 2019

Member, The 2017 Charles A. LeMaistre Outstanding Achievement Award Committee, 2017

Committee Member, Bridge Funding Advisory Committee, 2016 - 2022

Board Member, MD Anderson Physician Advisory Board, 2016 - 2019

Member, Search Committee for Emergency Medicine Chair, 2016 - 2016

Senator, Faculty Senate, 2016 - 2019

Member, Promotion and Tenure Committee, 2016 - 2018

Member, ASCO Scientific Program Committee, 2016 - 2017

Member, Translational Research Strategic Planning--Therapeutic Discovery & Development Subcommittee, 2015 - 2019

Voting member, Immunotherapy Executive Committee, 2015 - 2017

Research faculty representative, Division of Cancer Medicine Executive Meeting, 2014 - 2016

Member, Center for Inflammation and Cancer, 2014 - 2016

Member, Search Committee for GU Medical Oncology Research Faculty, 2014 - 2014

Member, Search Committee for Chair of the Department of Pathology, 2014

Member, MD Anderson Mock Study Section, 2014

Member, Multidisciplinary Research Advisory Committee (MRAC), 2013 - 2014

Member, K12 Advisory Committee, 2012 - 2013

Member, Technology Review Committee, 2012 - 2013

Member, Cancer Genetics and Epigenetics Core, 2012 - 2013

Member, MD Anderson Moon Shots Steering Committee, 2012 - 2013

Member, Clinical Research Impact Committee, 2008 - 2009

Reviewer, Institutional Research Grant Committee, 2007 - 2008

Member, Institutional Biosafety Committee, 2006

Senator, Faculty Senate, 2005 - 2008

Member, Clinical Research Committee II, 2005 - 2006

Member, Division of Cancer Medicine Fellowship Committee, 2005 - 2012

Member, DoCM Research Sub-Committee, 2003 - 2004

Member, Transfusion Committee, 2002 - 2003

Member, Clinical Research Committee I, 2001 - 2004

Member, MD Anderson International Spain Committee, 2001 - 2002

Honors & Awards

Professional Memberships

Selected Publications

Selected Presentations & Talks

Local Presentations

2025. An academic career focused on leukemia. Invited. Calabresi Master Class. Houston, Texas, US.
2024. MDS ASH update 2024. Conference. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.
2024. Can We Cure MDS?. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2024. MDS Progression: Mechanistic Insights. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2024. The MDACC MDS program in 2024. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. MDS ASH Update 2023. Conference. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.
2023. MDS. Conference. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.
2023. Translational and Clinical Advances in MDS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. Progress in MDS as MD Anderson and globally. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. An update on the treatment of lower risk MDS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. MDS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. Update on the MDS Program at MD Anderson Cancer Center. Conference. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.
2023. targeting clonal hematopoiesis. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. Deliberating on the Ethical Treatment Recommendations for Patients at the Crossroads. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. Academic Life. Conference. UT-Houston Medical School. Houston, TX, US.
2022. ASH Update on MDS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. An update on MDS MDACC clinical trials program. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. MDS at MDACC 2022. Conference. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.
2021. ASH Update - MDS. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.
2021. MDS/AML Moon Shot. Conference. The University of Texas MD Anderson Cancer Center. Houston, Texas, US.
2021. Treatment of MDS in 2021 - An ASH Update. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2020. Therapies and Patient Treatment Options. Conference. MDS Foundation. Houston, TX, US.
2019. ASH MDS Update. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2019. Understanding of Time-based Response Milestones and Monitoring in Patients with CML. Conference. CancerNet, LLC. Houston, TX, US.
2019. High risk MDS/AML: A New Entity. Conference. Aptitude Health. Houston, TX, US.
2019. Breaking MDS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2019. Deconstructing MDS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Deconstructing MDS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Case based lecture on Novel therapies for low-risk MDS. Conference. Baylor College of Medicine. Houston, TX, US.
2018. Translational research in myelodysplastic syndromes. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. What is new and exciting in MDS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2017. MDS/AML Moon Shot: A Molecular Immunotherapy-Targeted Program. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2017. Toward a Cure for Myelodysplastic Syndromes (MDS). Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2014. Myelodysplastic Syndromes. Conference. The 2014 Baylor College of Medicine/MD Anderson Cancer Center Hematology and Medical Oncology Board Review. Houston, TX, US.
2013. MDS-AML Moon Shot. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Innate Immunity Alterations in Myelodysplastic Syndrome (MDS). Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Treatment of Myelodysplastic Syndromes (MDS). Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Innate immunity alterations in MDS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2011. Treatment of Myelodysplastic Syndromes (MDS) – Dacogen® (decitabine) for Injection. Conference. Eisai Dacogen® Speakers Bureau Program. Houston, TX, US.
2010. MDS. Conference. Michael E. DeBakey VA Medical Center. Houston, TX, US.
2009. Problems in MDS. Conference. Michael E DeBakey VA Medical Center. Houston, TX, US.
2007. Update on MDS. Conference. Memorial Hospital Oncology Consultants. Houston, TX, US.
2004. An epigenetic approach to the treatment of leukemia and myelodysplastic syndromes. Conference. The Methodist Hospital. Houston, TX, US.
2002. Leukemia: Clinical Trials. Conference. Windsor Village. Houston, TX, US.
2001. Chronic Lymphocytic Leukemia. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2001. Acute Myeloid Leukemia. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2001. Treatment of Breast Cancer. Conference. UT-Houston Medical School. Houston, TX, US.
A Total Approach to Myelodysplastic Syndromes. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
Integrating epigenetic information in the prognosis and treatment of patients with leukemia. Visiting. UT MD Anderson Cancer Center. Houston, TX, US.
Epigenetic Alterations in Leukemia: Prognostic and Therapeutic Implications. Visiting. UT MD Anderson Cancer Center. Houston, TX, US.
Innate immunity alterations in MDS. Visiting. Albert Einstein College Medicine. New York, NY, US.
Epigenetic Therapy. Visiting. UT MD Anderson Cancer Center. Houston, TX, US.
Treatment of MDS: An update from ASH 2016. Visiting. UT MD Anderson Cancer Center. Houston, TX, US.
An Integrated Approach to MDS. Visiting. UT MD Anderson Cancer Center. Houston, TX, US.
Update on Treatment of Low Risk MDS. Visiting. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
Myelodysplastic Syndromes. Visiting. Taiho Oncology. Princeton, NJ, US.
The anti-leukemic activity of acetyl transferase inhibitors. Visiting. UT MD Anderson Cancer Center. Houston, TX, US.
Progress and problems in MDS. Visiting. UT MD Anderson Cancer Center. Houston, TX, US.
Progress in MDS. Visiting. UT MD Anderson Cancer Center. Houston, TX, US.
Update on MDS from ASH '09. Visiting. UT MD Anderson Cancer Center. Houston, TX, US.
Advances in Therapy of MDS. Visiting. Massachusetts General Hospital. Boston, MA, US.

2022. MDS at MDACC 2022. Conference. MD Anderson Cancer Center, US.
2022. Update on MDS. Conference. Baylor College of Medicine, US.
2020. MDS Part 2. Conference. MD Anderson Cancer Center. Houston, US.
2020. MDS. Conference. MD Anderson Cancer Center. Houston, US.
2020. Progress in the treatment of MDS at MD Anderson Cancer Center. Conference. MD Anderson Cancer Center, US.
2020. Incorporating New Prognostic Scores in MDS into Clinical Trials. Conference. Dava Oncology. Dallas, TX, US.
2019. Myelodysplastic Syndromes. Conference. prIME Oncology. Houston, New York, Atlanta, US.
2018. Staging and Scoring Systems for Myelodysplastic Syndrome. Conference. BioMedical Learning Institute. Dallas, TX, US.
2018. Management of Higher-risk Myelodysplastic Syndrome. Conference. BioMedical Learning Institute. Dallas, TX, US.
2018. Assessment and Management of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia. Conference. BioMedical Learning Institute. Dallas, TX, US.
2017. Update on MDS clinical trials at MDACC. Conference. The University of Texas MD Anderson Cancer Center, US.
2017. What did I learn on MDS at ASH 2016. Conference. The University of Texas MD Anderson Cancer Center, US.
2016. Oral presentations from ASH 2016. Conference. The University of Texas MD Anderson Cancer Center, US.
2012. Translational implications of epigenetic information in leukemia. Conference. The University of Texas MD Anderson Cancer Center. Round Top, TX, US.
2011. Risk Stratification and Treatment of Principles in AML. Conference. Fred Hutchinson Cancer Research Center. Seattle, WA, US.
2008. Progress in MDS. Conference. Victoria Hospital. Victoria, TX, US.
2008. Progress in MDS. Conference. Annual Meeting of the TOPA. Dallas, TX, US.
2007. Advances in MDS. Conference. Bayshore Hospital. Pasadena, TX, US.
2007. Novel agents for management of MDS. Conference. Annual Meeting of the TOPA. Dallas, TX, US.
2006. Updates on the treatments of myelodysplastic syndromes. Conference. Medical Center of McKinney. McKinney, TX, US.
2006. Updates on the Treatments in Myelodysplastic Syndromes. Conference. Texas Hematology/Oncology Center, PA. McKinney, TX, US.
2006. Valley Baptist Hospital Tumor Board Conference. Conference. Valley Baptist Hospital. Harlingen, TX, US.
2005. Use of 5-azacytidine in myelodysplastic syndrome. Conference. El Paso Cancer Treatment Center. El Paso, TX, US.
2004. New Advances in the Treatment of CML. Conference. Christus St. Elizabeth Hospital. Beaumont, TX, US.
Hematologic Malignancies Demystified: A Critical Appraisal of Data from 2017. Conference. prIME Oncology, US.

2025. Novel approaches and approvals in MDS. Invited. Myeloid Malignancy Workshop. New York, NY, US.
2024. Clinical needs Personalized treatment approaches for MDS/Studies matching new diagnostic approaches with improved treatments. Invited. Myelodysplastic Syndromes (MDS) Workshop. Bethesda, MD, US.
2023. Clinical Experience and Future Prospects with IRAK4 Inhibition in MDS. Invited. Curis, US.
2023. Management of Lower-Risk Myelodysplastic Syndromes. Invited. NCCN. San Francisco, CA, US.
2023. “Incorporating genomic information in the treatment of MDS”. Invited. Cancer Genomics Consortium. St. Louis, MO, US.
2023. Management of Lower-Risk Myelodysplastic Syndromes. Invited. 2023 Hematologic Malignancies Congress. San Francisco, CA, US.
2023. Advancing Drug Development in Myelodysplastic Syndromes. Invited. FDA & NCI, US.
2022. Orals HMA's. Invited. AAMDS, US.
2022. Treatments for MDS and Secondary AML. Invited. AAMDS. Bethesda, MD, US.
2021. Personalized therapy is ready for prime time in MDS. Invited. MDS 2021 Symposium, US.
2021. How I Treat MDS. Invited. Infomed, US.
2021. MDS Panel. Invited. NCCN Myelodysplastic Syndromes Panel, US.
2021. Treatment of MDS in 2021 - An ASH Update. Invited. Hematologic Malignancies Demystified 2021, US.
2020. Deconstructing MDS @ The Inaugural Edward P. Evans Seminar in MDS. Invited. Dana-Farber Cancer Institute & The Jimmy Fund, US.
2020. Oral Therapies in MDS. Invited. DoctaForum and MD Anderson Cancer Center Madrid, US.
2020. Treatment of Lower-Risk MDS and Role of Inflammation. Invited. Novartis, US.
2020. Landscape of MDS Therapy. Conference. Novartis, US.
2020. Treatment of Higher-Risk MDS. Invited. Novartis, US.
2020. Reblozyl MDS General Session. Invited. Bristol-Myers Squibb. Miami, FL, US.
2020. MDS KOL Case Study Workshop. Invited. Bristol-Myers Squibb. Maimi, FL, US.
2020. Myelodysplastic Syndromes. Invited. Hematologic Malignancies Demystified. Houston, TX, US.
2020. Myelodysplastic Syndromes. Invited. Hematologic Malignancies Demystified. Atlanta, GA, US.
2020. Myelodysplastic Syndromes. Invited. Hematologic Malignancies Demystified. New York, NY, US.
2020. Myelodysplastic Syndromes. Invited. Hematologic Malignancies Demystified. Chicago, IL, US.
2019. Data on Treatment Options of Myelodysplastic Syndromes. Invited. AmerisourceBergen. Las Vegas, NV, US.
2019. New questions in MDS. Conference. Global Academic Programs Conference: Innovation & Collaboration to Transform Patient Care. Houston, TX, US.
2019. Hematologic Malignancies Demystified: Myelodysplastic Syndromes. Conference. prIME Oncology. Houston, TX, US.
2019. Hematologic Malignancies Demystified: Myelodysplastic Syndromes. Conference. prIME Oncology. Atlanta, GA, US.
2018. Poster Presentation: Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients immune related arthritis. Invited. SITC. Washington, DC, US.
2018. Problems Ahead in MDS: What is Next?. Invited. Society of Hematologic Oncology. Houston, TX, US.
2018. MDS: Understanding your Disease and Treatment Options. Invited. AAMDS. Houston, TX, US.
2018. AML: Understanding your Disease and Treatment Options. Invited. AAMDS. Houston, TX, US.
2018. High Risk MDS. Invited. High Risk MDS. Miami, FL, US.
2018. Optimizing TKi in CML. Invited. Optimizing TKi in CML. Miami, FL, US.
2018. NGS in Hematologic Neoplasms, Clinician View. Invited. NEO Genomics. Dana Point, CA, US.
2018. Hematology Demystified: Update on MDS. Conference. prIME Oncology. Houston, US.
2018. Hematology Demystified: Update on MDS. Invited. prIME Oncology. Atlanta, US.
2018. Hematology Demystified: Update on MDS. Invited. prIME Oncology. New York, US.
2018. Hematology Demystified: Update on MDS. Invited. prIME Oncology. Chicago, US.
2017. The NLRP3 Inflammasome As Driver of the MDS Phenotype. Invited. Society of Hematologic Oncology. Houston, TX, US.
2017. Harnessing Immunotherapeutics for the Treatment of MDS. Invited. Society of Hematologic Oncology. Houston, TX, US.
2017. Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant. Invited. Best of ASCO. New Orleans, LA, US.
2017. Myelodysplastic Syndrome: Management Beyond Hypomethylating Agent. Invited. University of Nebraska Medical Center. Omaha, NE, US.
2016. The goals of first-line and salvage therapies for MDS by risk group in practice, and how well current established (what should be used as the control arm?) and investigational treatments are meeting those goals. Invited. FDA. Silver Springs, MD, US.
2016. Myelodysplastic Syndromes. Invited. prIME Oncology. San Francisco, CA, US.
2016. Myelodysplastic Syndromes. Invited. prIME Oncology. Houston, TX, US.
2016. Myelodysplastic Syndromes. Invited. prIME Oncology. Chicago, IL, US.
2016. Myelodysplastic Syndromes. Invited. prIME Oncology. New York, NY, US.
2015. Update on MDS. Invited. Imedex. Alexandria, VA, US.
2014. Update on MDS Research. Conference. MDS Research Summit. Philadelphia, PA, US.
2014. How Cardeza helped me focus on MDS and AML. Conference. Cardeza 75th Anniversary. Philadelphia, PA, US.
2014. Treatment of Lower Risk MDS that has Failed HMA and Lenalidomide. Invited. Treatment of Lower Risk MDS that has Failed HMA and Lenalidomide. Houston, TX, US.
2013. Advances in the Treatment of MDS. Invited. Medical Oncology and Hematology 2013: Multidisciplinary Approaches that Improve Coordination of Care. Houston, TX, US.
2013. S1203, “A Randomized Phase III Study of Standard CytarabineS1203, “A Randomized Phase III Study of Standard Cytarabine plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). Invited. SWOG Fall 2013 Group Meeting. Chicago, IL, US.
2012. S1203, "A Randomized Phase III Study of Standard Cytarabine plus Daunomycin (7 + 3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML).". Invited. SWOG (formerly the Southwest Oncology Group). Chicago, IL, US.
2012. Progress in MDS. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Treatment of Lower Risk MDS. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. New MDS Strategies. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Therapy of MDS. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Personalization of Therapy for MDS: The Role of Biology, Risk Stratification, and Evolving Therapies. Conference. NCCN 7th Annual Congress: Hematologic Malignancies. New York, NY, US.
2011. Myelodysplastic Syndrome in 2011. Invited. University of Minnesota and Association of VA Hematology/Oncology. Kansas City, MO, US.
2011. Nucleoside Analogues. Invited. MDS 2011. Edinburgh.
2011. How Do I Approach MDS?. Conference. Hematology/Oncology Education Conference. Scottsdale, AZ, US.
2011. Treatment of MDS. Invited. BMT Tandem Meetings. Honolulu, HI, US.
2011. Myelodysplastic Syndromes. Invited. prIME Oncology. Houston, TX, US.
2011. Myelodysplastic Syndromes. Invited. Seventh Annual Hematology Conference: An Update on Selected ASH Topics. Knoxville, TN, US.
2010. Advances in the Management of Patients with Myeloid Neoplasms. Invited. University of Nebraska Medical Center. Hollywood, FL, US.
2010. Debate: Role of Allogeneic SCT in MDS--Minimal Benefit in MDS. Invited. Hematologic Malignancies Houston 2010. Houston, TX, US.
2010. Updates on Biology and Therapy of MDS. Invited. Hematologic Malignancies Houston 2010. Houston, TX, US.
2010. Evolving strategies for the treatment of MDS. Invited. NIH. Bethesda, MD, US.
2010. Lenalidomide is not the best choice for most deletion 5q patients. Invited. Imedex. New York, NY, US.
2010. Novel and Evolving Therapeutic Strategies for MDS. Invited. Imedex. New York, NY, US.
2010. New Approaches in the Treatment and Management of MDS and AML. Invited. Excel Continuing Education. New Orleans, LA, US.
2010. Myelodysplastic Syndromes. Invited. Hematology 2010: Advances in Science, Emerging Data, and Novel Therapeutics. San Francisco, CA, US.
2010. Myelodysplastic Syndromes. Invited. prIME Oncology. New York, NY, US.
2010. Managing Higher-Risk Disease: Hypomethylating Agents and Beyond. Invited. USF Health, Moffitt Cancer Center, MD Anderson Cancer. Lake Buena Vista, FL, US.
2009. Emerging Strategies for the Treatment of AML and MDS: Progress and Challenges. Invited. 51st Meeting American Society of Hematology. New Orleans, LA, US.
2009. Myelodysplastic syndromes: risk factors, classification--when to treat. Invited. 5th Annual Clinical Breakthroughs & Challenges in Hematological Malignancies. Orlando, FL, US.
2008. Epigenetic Therapy of Leukemia. Invited. University of California, San Francisco, Gladstone Cancer Center. San Francisco, CA, US.
2008. Myeloid Leukemias and MDS. Invited. Lombardi Comprehensive Cancer Center at Georgetown University Hospital, ASH 2007 Highlights. Tysons Corner, VA, US.
2008. Update on methyltransferase inhibitors. Invited. 4th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies. Lake Buena Vista, FL, US.
2007. Clinical and Molecular Implications of Epigenetic Alterations in Human Leukemia. Invited. American Association of Cancer Research Meeting. Philadelphia, PA, US.
2007. Update on Treatment Options in MDS and AML. Invited. Chemotherapy Foundation Symposium XXV. New York, NY, US.
2007. Epigenetics and Cancer Therapy. Invited. Piedmont Oncology Association 28th Annual Symposium. Myrtle Beach, SC, US.
2007. MGCD 0103: The first class-selective HDAC-i?. Invited. Johns Hopkins Workshop on Clinical Targeting of Epigenetic Changes in Cancer Therapeutics. Phoenix, AZ, US.
2006. New strategies for MDS: epigenetic-modulating drugs. Invited. Satellite Symposium at ACCP Meeting. St. Louis, MO, US.
2006. Emerging Agents for MDS. Invited. Current Trends in Leukemia, Lymphoma, and Myeloma. Kansas, MO, US.
2005. Current Topics in Myelodysplastic Syndromes. Invited. ONS Learning Institution. Phoenix, AZ, US.
2005. MDS/decitabine: new data from the Phase III trial. Invited. Chemotherapy Foundation Symposium XXIII. New York, NY, US.
2005. Epigenetic information for the treatment and prognostication of cancer. Invited. Moving Biosensors to Point-of-Care Cancer Diagnostics. Rockville, MD, US.
2005. What are consequences of epigenetic therapy. Invited. Horizon Symposium. Portland, ME, US.
2005. Advances in the treatment of leukemia and MDS. Invited. Oklahoma City Oncology Society Annual Meeting. Oklahoma City, OK, US.
2005. Results of a phase 1 study of oral SAHA in leukemia. Invited. Johns Hopkins Clinical Targeting of Epigenetic Changes. Charleston, SC, US.
2004. Results of a Phase I/II Study of the Combination of 5-aza-2-deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia. Invited. 2004 American Society of Hematology Annual Meeting, US.
2003. Metastatic disease in the leptomeninges: from treatment to prevention. Invited. 2003 Society of NeuroOncology (SNO) Meeting. Keystone, CO, US.
2003. Development of Decitabine in AML, Myeloma, and Hemoglobinopathies - AML. Invited. Development of Decitabine in AML, Myeloma, and Hemoglobinopathies - AML. Sonoma, CA, US.
2003. Clinical development of HDAC inhibitor and demethylating agents. Invited. Workshop on Clinical Translation of Gene Re-expres. Baltimore, MD, US.
1998. Treatment of AML. Conference. The Cardeza Foundation For Hematologic Research. Philadelphia, PA, US.
1997. Approach to the Treatment of AML. Conference. The Cardeza Foundation For Hematologic Research,. Philadelphia, PA, US.
1996. Appropriate prescribing for hispanic patients. Invited. Cycle of conferences in Camp Hill. Pittsburg, PA, US.
1994. Appropriate prescribing for hispanic patients. Invited. The Pennsylvania Medical Society/MSA-MEDNET. Harrisburg, PA, US.
1993. DNA-Toposisomerase II In Hematological Malignancies. Conference. The Cardeza Foundation For Hematologic Research. Philadelphia, PA, US.

2025. State of the art of myelodysplastic neoplasms in 2025. Invited. International Congress of Hematology. Mexico City, MX.
2025. Myelodysplastic Syndromes and Clonal Hematopoiesis. Invited. 2025 Highlights of ASH in Asia-Pacific. Yokohama, JP.
2025. Targeted therapy and new targets in high-risk MDS. Invited. SOHO Spain 2025. Madrid, ES.
2024. Low-risk MDS. Invited. 2nd SOHO Mena. Beirut, LB.
2024. New approaches in the treatment of patients with high-risk MDS. Invited. National Congress SEHH. Palma de Mallorca, ES.
2024. Towards a cure in myelodysplastic syndromes. Invited. National Congress SEHH. Palma de Mallorca, ES.
2024. A Total Approach to MDS. Invited. SOHO 2024 Annual Meeting. Houston, US.
2024. Next Questions: Myelodysplastic Syndromes. Invited. SOHO 2024 Annual Meeting. Houston, US.
2024. Resetting Standards in MDS: New Principles of Integrating Innovative Therapy Into Risk-Adapted Decision-Making. Invited. SOHO 2024 Annual Meeting. Houston, US.
2024. Low-risk myelodysplastic syndrome: Therapeutic approach and future perspectives. Invited. MYELOMA, LYMPHOMA AND LEUKEMIA SYMPOSIUM. Bogota, CO.
2024. LMA clinical case format. Invited. MYELOMA, LYMPHOMA AND LEUKEMIA SYMPOSIUM. Bogota, CO.
2024. HMAs -- a party of one. Invited. 9th Translational Research Conference Myelodysplastic Syndromes. Budapest, HU.
2024. Recent Advances and future therapeutic strategies in MDS. Invited. 2024 Korean Society of Hematology International Conference & 65th Annual Meeting (ICKSH 2024). Seoul, KR.
2024. Immune checkpoint inhibitors in AML and MDS. Invited. Studio ER Congressi. Bologna, IT.
2023. THERAPEUTIC ADVANCES IN MYELOID NEOPLASMS: MDS/LMA. Invited. Argentine Congress of Hematology. Mar de Plata, AR.
2023. Management of High-Risk Myelodysplastic Syndromes in MDACC: a total approach. Invited. Society of Hematologic Oncology - Italy. Rome, IT.
2023. Treatment of CCUS. Invited. MD Anderson Madrid. Madrid, ES.
2023. New approaches for anemia in MDS. Invited. MD Anderson Madrid. Madrid, ES.
2023. Management of High-risk MDS. Invited. SOHO MENA 2023. Beirut, LB.
2023. Management of TP53 MDS/ AML. Invited. SOHO MENA 2023. Beirut, LB.
2023. Next Questions in MDS. Invited. SOHO MENA 2023. Beirut, LB.
2023. New approaches in low-risk MDS. Invited. Catalan Institute of Oncology in Hospitalet (Barcelona). Barcelona, ES.
2022. Update on clinical trials for MDS and AML. Invited. Argentine Society of Hematology, AR.
2022. Innovative focus in Low-Risk MDS: from clinical trial to Real–Life management. Invited. BMS. Buenos Aires, AR.
2022. Redefining High Risk: from epigenetics (NGS) to prognostic scores. Invited. BMS. Buenos Aires, AR.
2022. SOHO State of the Art & Next Questions: MDS. Invited. e XIII Eurasian Hematology Oncology Congress (EHOC 2022). Istanbul, TR.
2022. SOHO Session XIV: Next Questions. Invited. Society of Hematologic Oncology. Houston, US.
2022. Management of Higher Risk MDS in MDACC: a total approach. Invited. SOHO Italy 4th Annual Conference. Rome, IT.
2022. Total Approach to MDS. Invited. Society of Hematologic Oncology. Houston, US.
2022. State of the Art Lecture Series in Hematologic Malignancies - Myelodysplastic Syndrome. Invited. Philippine College of Hematology and Transfusion Medicine, PH.
2022. Progress in lower risk MDS: time to change current paradigm?. Invited. Cancer Research Centre of Salamanca, ES.
2022. BCL2 inhibitors: Beyond AML, any role for MDS?. Invited. European Hematology Association (EHA), AT.
2022. TAKEAIM LEUKEMIA - A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS. Invited. Curis, AT.
2022. Myelodysplastic Syndromes: Beyond ESA and HMA, what is the future for the ttt of MDS?. Invited. European Hematology Association (EHA), AT.
2022. Impact of Cytopenias in Low-Risk Myelodysplastic Syndromes. Invited. XII Reunion Anual GESMD. Madrid, ES.
2022. Myelodysplasia Syndrome. Invited. Mumbai Hematology Group, US.
2021. New challenges in therapeutic approach of High Risk Myelodysplastic Syndromes: therapies in combination and targeting molecular targets. Invited. Andalusian Group Myelodysplastic Syndromes, US.
2021. Hypomethylating agents in AML. Invited. National Congress of Hematology, US.
2021. Therapeutic alternatives in high-risk myelodysplasia. Invited. XXV Argentine Congress of Hematology, US.
2021. Maintenance Therapy in AML. Invited. Bristol Myers Squibb - Chile, US.
2021. Nuevas opciones terapéuticas en los pacientes de alto riesgo, ¿es el momento de las terapias combinadas?. Invited. 63rd Annual Meeting of the Spanish Society of Hematology and Haemotherapy and 37th National Congress of the Spanish Society of Thrombosis and Haemostasis, US.
2021. 1º Curso Práctico Manejo de los nuevos agentes en LMA (Plazas limitadas) - Moderator. Invited. MD Anderson Madrid Acute Leukemia Meeting, US.
2021. Incorporación de inhibidores de Bcl-2 en los SMD. Invited. MD Anderson Madrid Acute Leukemia Meeting, US.
2021. Immunotherapy in Myelodysplastic Syndromes. Invited. MD Anderson Madrid, US.
2021. Debate: Personalized therapy Is ready for prime time in MDS. Invited. 16th International Congress on Myelodysplastic Syndromes (MDS 2021), US.
2021. Molecular Target in AML. Invited. ASH-SAH Joint Symposium, US.
2021. Next Questions: Myelodysplastic Syndromes. Invited. SOHO, US.
2021. Use of Oral Hypomethylating Agents in MDS. Invited. SOHO, US.
2021. Session II: Myelodysplastic Syndromes. Invited. SOHO, US.
2021. MDS/AML: Current treatment options for elderly patients. Invited. Philippine College of Hematology and Transfusion Medicine, US.
2021. MDS/AML: Maintenance therapy in AML. Invited. Philippine College of Hematology and Transfusion Medicine, US.
2021. Therapeutic Progress in MDS and AML. Invited. 9th InterAmerican Oncology Conference, US.
2021. Novel targets in MDS. Invited. European Hematology Association (EHA), US.
2021. A PHASE 1, DOSE ESCALATION TRIAL WITH NOVEL ORAL IRAK4 INHIBITOR CA-4948 IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME – INTERIM REPORT. Invited. European Hematology Association (EHA), US.
2021. The future treatments for MDS patients. Invited. Sheba City of Health, US.
2021. Advances in MDS. Invited. Mumbai Hematology Group, US.
2021. Update Treatment MDS: New Agents. Invited. Puerto Rico Hematology and Medical Oncology Association, US.
2021. Update Treatment MDS: New Agents. Invited. Puerto Rico Hematology and Medical Oncology Association, US.
2021. The Best of ASH in Myelodysplastic Syndromes. Invited. Agrupación Mexicana para el Estudio de la Hematología A.C, US.
2021. Treatment in Patient Refractory to Hypomethylants. Invited. Grupo Espanol de Sindromes Mielodisplasicos, US.
2021. Clinical Update In Myelodysplastic Syndromes. Invited. 25th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myelomas, US.
2020. Myelodysplastic syndrome Current treatment first line and refractory to hypomethylating. Invited. National Cancer Institute - Mexico, US.
2020. State of the Art & Next Questions: Myelodysplastic Syndromes. Invited. Society of Hematologic Oncology, US.
2020. SOHO Updates on AML. Invited. Eurasian Hematology Oncology Group, US.
2020. SOHO Updates on MDS. Invited. Eurasian Hematology Oncology Group, US.
2020. Advanced therapy in MDS. Invited. Japanese Society of Hematology, US.
2020. COVID 19 Session Presentation. Invited. DoctaForum and MD Anderson Cancer Center Madrid, US.
2020. Immunotherapy approaches in MDS. Invited. DoctaForum and MD Anderson Cancer Center Madrid, US.
2020. Myelodysplastic Syndromes: State of the art in USA - Emerging frontline HMA based regimens. Invited. SOHO - 2nd Italian Conference, US.
2020. Next Questions: Myelodysplastic Syndromes. Invited. SOHO. Houston, US.
2020. Development of Oral HMAs For MDS. Invited. SOHO. Houston, US.
2020. Future of MDS. Invited. Le 11ème Congrès d’Oncologie Francophone & the 8th Lebanese Gynecologic Oncologic Group, US.
2020. Therapies to bring resistant acute leukemia into HSCT. Invited. European Society for Blood and Marrow Transplantation, US.
2020. Biology and Staging Systems. Invited. Eurasian Hematology Oncology Group, US.
2020. Management of Lower-Risk MDS. Invited. Eurasian Hematology Oncology Group, US.
2020. Acute Leukemia Webinar I. Invited. FUNDALEU, US.
2020. Tratamiento contemporáneo de los síndromes mielodisplásicos. Invited. Agrupación Mexicana para el Estudio de la Hematología A.C, US.
2020. Novel Treatments for MDS I. Invited. Medco, US.
2020. Personalized Treatment in MDS. Invited. European School of Oncology, US.
2020. What's in the pipeline?. Invited. MDS Foundation. Tel Aviv, IL.
2019. Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine. Invited. 61st American Society of Hematology Annual Meeting. Orlando, US.
2019. NPM1 mutations define a specific subgroup of MD and MDS/MPN patients with favorable outcomes and intensive chemotherapy. Invited. Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz. Madrid, ES.
2019. Breaking Myelodysplastic Syndrome. Invited. Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz. Madrid, ES.
2019. Clinical Case Reviews Acute Leukemias: Unusual cases and rare leukemias. Conference. MD Anderson Cancer Center Madrid. Madrid, ES.
2019. Targeting apoptosis in Melodisplastic sindromes. Invited. MD Anderson Cancer Center Madrid. Madrid, ES.
2019. Breakfast with the Expert: State of the art of MDS in MDACC. Invited. Society of Hematologic Oncology - Italy. Rome, IT.
2019. State of the art Updatein MDACC: Emerging Targeted Therapeutics for MDS. Invited. Society of Hematologic Oncology - Italy. Rome, IT.
2019. Update on AML Management in 2019. Invited. The Regional Academy for Clinical Hematology. Beirut, LB.
2019. Clinical development of epigenetic modifiers in human leukemia. Invited. Josep Carreras Leukemia Research Institute. Barcelona, ES.
2019. Next Questions: Myelodysplastic Syndromes. Invited. Society of Hematologic Oncology. Houston, US.
2019. MDS State of the Art Update: Emerging Targeted Therapeutics for MDS. Invited. Society of Hemtologic Oncology. Houston, US.
2019. Emerging Utility of immune Checkpoint Inhibitors in Myelodysplastic Syndromes. Invited. 24th Congress of the European Hematology Association. Amsterdam, NL.
2019. Relevance of Measurable Residual Disease. What's the chosen method in 2019?. Invited. FUNDALEU. Buenos Aires, AR.
2019. New genetic and molecular markers for the diagnosis and prognosis of AML. Invited. FUNDALEU. Buenos Aires, AR.
2019. Incorporating immunotherapy in AML. Invited. FUNDALEU. Buenos Aires, AR.
2019. Treatment directed at AML: Induction, consolidation, and maintenance. Invited. FUNDALEU. Buenos Aires, AR.
2019. Do We Know How to Use Hypomethylating Agents in Myeloid Disorders?. Invited. 2019 ASCO Annual Meeting. Chicago, US.
2019. Long Term Survival Results and prognostic Factors of Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) Treated with Guadecitabine. Invited. MDS Foundation. Copenhagen, DK.
2019. Combining Hypomethylation Drugs and Immune Check Point Inhibitors. Invited. MDS Foundation. Copenhagen, DK.
2019. Development of an Oral Hypomethylating Agent (ASTX727) as a Fixed Dose Combination (FDC) of Decitabine and CDA Inhibitor Cedazuridine. Conference. MDS Foundation. Copenhagen, DK.
2019. Management of Lower-risk MDS. Invited. Eurasian Hematology Oncology Summit. Istanbul, TR.
2019. Biology and Staging Systems. Invited. Eurasian Hematology and Oncology Summit. Istanbul, TR.
2019. Management of Lower-risk MDS. Invited. Hikma Cancer Network. Lisbon, PT.
2019. Biology and staging systems. Invited. Hikma Cancer Network. Lisbon, PT.
2019. Hematologia. Invited. ASOFARMA. Miami, US.
2018. Updates in MDS and AML. Conference. 9th Annual Clinical Update in Hematology. Abu Dhabi, AE.
2018. Myelodysplastic Syndromes. Conference. Lebanese Society of Hematology and Blood Transfusion. Beirut, LB.
2018. Acute Myeloid Leukemia. Invited. Lebanese Society of Hematology and Blood Transfusion. Beirut, LB.
2018. Immunotherapy in AML. Invited. Doctaforum Medical Events. Madrid, ES.
2018. Current and future therapy of MDS. Invited. Agrentinian Society of Hematology. Buenos Aires, AR.
2018. Minimal Residual Disease: What method? When and how to interpret results?. Invited. FUNDALEU. Buenos Aires, AR.
2018. New drugs and applications in MDS and AML. Invited. FUNDALEU. Buenos Aires, AR.
2018. Clonal hematopoiesis. Invited. FUNDALEU. Buenos Aires, AR.
2018. Integrating molecular profile in AML ad MDS. Invited. FUNDALEU. Buenos Aires, AR.
2018. Update on the diagnosis and treatment of MDS. Invited. Latinoamericano de Hematologia. Cartegena de Indias, CO.
2018. Treatment of acute myeloblastic leukemia: whats new?. Invited. Latinoamericano de Hematologia. Cartagena de Indias, CO.
2018. A PHASE II CLINICAL TRIAL OF GUADECITABINE (SGI-110) FOR PATIENTS WITH PREVIOUSLY UNTREATED MYELODYSPLASTIC SYNDROME. Invited. EHA, SE.
2018. Meaningful Patient-Reported Outcomes – how to lean from real-life experience in clinical research. Conference. EHA. Stockholm, SE.
2018. Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant. Invited. ASCO. Chicago, US.
2018. Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant. Conference. ASCO. Chicago, US.
2018. Current and Future Treatments of MDS. Invited. AAMDS. Puerta Vallarta, MX.
2018. Biology of MDS and Prognostic systems. Invited. Hikma Cancer Network, JO.
2018. How I treat higher-risk MDS. Conference. Hikma Cancer Network, JO.
2018. Does Dose/Schedule Matter for HMA Based Therapy?. Invited. AA MDS International Foundation. Rockville, US.
2018. International Bone Marrow Failure Disease Scientific Symposium. Conference. Aplastic Anemia and MDS International Foundation. Rockville, US.
2017. How I Treat MDS and Myelodysplastic Syndromes. Invited. International Association for Comparative Research on Leukemia and Related Diseases. Houston, US.
2017. New options and treatment strategies in MDS. Invited. 14th Valencia MDS Symposium. Valencia, ES.
2017. AML: Challenges and Overview, New Approaches in AML Management, and Recent Updates in MDS. Invited. Celgene. Rome, IT.
2017. How I treat Azacitidine Failures. Invited. British Society for Haematology, UK MS Forum. Brighton Centre, GB.
2016. CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. Invited. Ash Annual Meeting. San Diego, US.
2016. SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). Invited. Ash Annual Meeting. San Diego, US.
2016. Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response. Invited. Ash Annual Meeting. San Diego, US.
2016. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Invited. Ash Annual Meeting. San Diego, US.
2016. Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment. Invited. Ash Annual Meeting. San Diego, US.
2016. Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS). Invited. Ash Annual Meeting. San Diego, US.
2016. Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures. Invited. Ash Annual Meeting. San Diego, US.
2016. A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy. Invited. Ash Annual Meeting. San Diego, US.
2016. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Invited. ASH Annual Meeting. San Diego, US.
2016. A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. Invited. Ash Annual Meeting. San Diego, US.
2016. Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study. Invited. Ash Annual Meeting. San Diego, US.
2016. Hypomethylating Agents in Acute Myeloblastic Leukemia, Present and Future. Invited. MD Anderson Madrid, Spain. Madrid, ES.
2016. Manejo de los Sindromes Mielodisplasicos. La vision de un experto. Invited. Jornada Latino Americana de la Sociedad Argentina de Hematologia. Buenos Aires, AR.
2016. Factors affecting prognostication and assessment of Minimal Residual Disease in MDS. Invited. Argentinian Society of Hematolog. Buenos Aires, AR.
2016. MDS Overview and Focus on Immunotherapy. Invited. Eurasian Hematology Summit. Istanbul, TR.
2016. How I treat MDS. Invited. Congres d'Oncologie Francophone & The Middle East. Beirut, LB.
2015. Epigenetics in clinical practice: SPOTLIGHT on decitabine in myelodysplasia and acute myeloid leukemia. Invited. HAEMATOCON 2015: 56th Annual Meeting of Indian Society of Haematology and Blood Transfusion. Bangalore, IN.
2015. What's New in MPN?. Invited. Saint George Hospital University Medical Center. Beirut, LB.
2015. Molecular Basis of MDS and Current Strategies in Paitents with MDS who are not Transplant Candidates. Invited. Congreso Venezolano de Hematologia. Caracas, VE.
2015. Update on MDS. Invited. EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY. Vienna, AT.
2015. Myelodysplastic Syndrome-Molecular Novelties, Therapy and Immunotherapy in 2015. Invited. Hematology Specialists Association. Istanbul, TR.
2015. How do I treat elderly AML patients?. Invited. Janssen, India, IN.
2015. MDS/AML in Young Patients: Clinical Cases. Invited. Celgene. Istanbul, TR.
2015. Beyond Diagnosis of MDS: How to Improve Survival?. Invited. Celgene. Istanbul, TR.
2014. Manejo actual en Mielodisplasia. Revision & MESA REDONDA: Eleccion Terapeutica en SMD: Como, Cuando y Aquien?. Conference. Associacion Mexicana de Sindrome Mielodisplasico, A.C. Puerto Vallarta, MX.
2014. Advances in MDS Disease Management. Invited. Janssen. Beijing, CN.
2014. Hacia la cura de los sindromes mielodisplasicos y de la leukemia mieloide aguda. Invited. Instituto de Espana Academia Asociada. Palma, ES.
2014. Actualizacion en el manejo de la lma del anciano. Conference. Sociedad Espanola de Hematologia y Hemoterapia. Madrid, ES.
2014. "The management of older patients with AML" and "Optimal frontline therapies for patients with MDS". Invited. MEMA 2014 Updates: Focus on Hematological Malignancies. Beirut, LB.
2014. Update on MDS. Invited. Lebanese Society of Medical Oncology National Forum. Beirut, LB.
2014. What is new in MDS?. Invited. Eurasion Hematology Forum. Istanbul, TR.
2014. MDS Update. Invited. Instituto Nacional de Cancerología (INCAN). Mexico City, MX.
2013. How I Treat: Bringing Science to Clinical Dilemmas. Invited. American Society of Hematology. New Orleans, US.
2013. Moderator and Speaker--Myelodysplastic syndrome: research and treatment. Invited. MDS Symposium. Bogota, CO.
2013. Controversies in MDS and Optimizing the Management of AML patients (MD Anderson Cancer Center perspective). Invited. Joint Meeting PETHEMA and MD Anderson Cancer Center. Seville, ES.
2013. "Myelodysplastic Syndromes" session chair. Invited. Society of Hematologic Oncology. Houston, US.
2013. Novel Therapeutics in MDS. Invited. Society of Hematologic Oncology. Houston, US.
2013. "Novel Strategies in MDS" meet the professor session. Invited. Society of Hematologic Oncology. Houston, US.
2013. Update on MDS. Invited. Washington Cancer Institute. Berlin, DE.
2013. "What is next for MDS?" poster discussant. Invited. ASCO. Chicago, US.
2013. How I treat higher-risk MDS. Conference. Hikma Cancer Network, JO.
2012. "Direcciones Futuras en SMD" and "Nuevos enfoques fisiopatogenicos en SMD". Invited. AMSM Iberoamerican MDS Simposio. Puerto Vallarta, MX.
2012. Actualizacion en Sindrome Mielodisplasico. Invited. Organiza Sociedad Chilena Hematologia. Santiago, CL.
2012. Advances in Treatment of MDS. Invited. II Curso Internacional de Hematopatologia. Lima, PE.
2012. Current Treatment of Myelodysplastic Syndrome RAEB type II and acute myeloid leukemia secondary to myelodysplasia. Invited. Asofarma. Cancun, MX.
2012. Diagnosis and management of low risk MDS: molecular markers and cytogenetic profile. Invited. Asofarma. Cancun, MX.
2012. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in elderly patients with newly diagnosed acute myeloid leukemia. Invited. 17th Congress of the European Hematology Association. Amsterdam, NL.
2012. New experimental drugs; Combination drug therapy. Invited. International Conference on Myelodysplastic Syndromes. Dublin, IE.
2012. Epigenetic and molecular changes in SMD; Algorithm for MDS treatment; Specific characteristics and treatment of AML in the elderly. Invited. Janssen Pharmaceutical Companies of Johnson & Johnson. Sao Paulo, BR.
2012. What to Make of All the MDS Prognostic Systems. Conference. Aplastic Anemia and MDS International Foundation. Bethesda, US.
2011. Síndromes mielodisplásicos. Invited. Reunión Nacional de la SEHH; XXVII Congreso Nacional de la SETH. Zaragoza, ES.
2011. ¿Cómo tomar Decisiones en el Tratamiento de los Síndromes Mielodisplásicos?. Invited. XX Congreso Argentino de Hematologia. Buenos Aires, AR.
2011. Subcomisión de Hematólogos Jóvenes. Leucemia Mieloblástica Aguda: Manejo de Diferentes Situaciones Clínicas. Invited. XX Congreso Argentino de Hematologia. Buenos Aires, AR.
2011. Treatment of MDS. Invited. 16th Congress of the European Hematology Association (EHA). London, GB.
2011. Sindromes Mielodisplasicos: nuevos abordajes terapeuticos. Invited. III Congreso Nacional de Hematologia. Panama City, PA.
2011. Leucemia mieloide aguda en el anciano. Invited. Congreso de la Asociacion Madrilena de Hematologia y Hemoterapia. Madrid, ES.
2011. Manejo de Mielodisplasico con Hipometilantes. Invited. SMD III Simposio Latino-Americano. Cartagena, CO.
2011. Bases moleculares y geneticas del SMD; Nueva clasificacion SMD; Factores pronosticos en SMD. Invited. SMD III Simposio Latino-Americano. Cartagena, CO.
2010. Prognosis in Myelodysplastic Syndromes. Invited. 52nd ASH Annual Meeting. Orlando, US.
2010. New Perspectives in Hematological Malignancies. Invited. Genzyme. Las Palmas, ES.
2010. Leucemia mieloide aguda en el anciano y otras leucemias "dificiles". Invited. Celgene. Barcelona, ES.
2010. Prognostic models in MDS. Invited. ASCO 2010 Annual Meeting. Chicago, US.
2010. Treatment of High Risk MDS and Novel Strategies. Invited. MD Anderson Cancer Center Symposium: Breakthroughs in Hematological Malignancies. Beirut, LB.
2010. Clinical and Prognostic Features in MDS, Classifications, Risk Models. Invited. MD Anderson Cancer Center Symposium: Breakthroughs in Hematological Malignancies. Beirut, LB.
2010. HDAC Inhibitor and Combination Therapy in MDS. Invited. Aplastic Anemia and MDS International Foundation. Bethesda, US.
2009. Advances in MDS. Invited. LI Reunion Nacional AEHH 25 Congreso Nacional SETH. Barcelona, ES.
2009. Current treatment of MDS. Invited. The HematOncology Conference. Rivera Maya, Quintana Roo, MX.
2009. High-risk MDS: HIDACi and ongoing trials at clinical trials.gov. Invited. International Conference on Myelodysplastic Syndromes. Mandelieu, FR.
2009. Management and treatment of thrombocytopenia. Invited. International Conference on Myelodysplastic Syndromes. Mandelieu, FR.
2009. Improving Outcomes in Myelodysplastic Syndromes. Invited. Current Status and Future of Anti-Cancer Targeted Therapies. Buenos Aires, AR.
2009. New Algorithms in the Prognosis and Treatment of MDS. Invited. II Annual Meetings of the Andalucia Society of Hematology. Malaga, ES.
2009. Clinical Relevance of Epigenetic Agents in Hematology. Invited. Spanish Department of Health. Madrid, ES.
2009. Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia. Conference. ASCO 2009 Annual Meeting. Orlando, US.
2009. Comorbidities and prognosis of myelodysplastic syndromes. Conference. ASCO 2009 Meeting Annual. Orlando, US.
2009. Feasibility of hypomethylating therapy in patients with renal insufficiency. Conference. ASCO 2009 Annual Meeting. Orlando, US.
2009. Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML). Conference. ASCO 2009 Annual Meeting. Orlando, US.
2009. The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). Conference. ASCO 2009 Annual Meeting. Orlando, US.
2009. Standard-of-Care approaches for myelodysplastic syndromes. Invited. ASCO 2009 Annual Meeting. Orlando, US.
2009. Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Conference. ASCO 2009 Annual Meeting. Orlando, US.
2009. Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The MD Anderson Cancer Center experience. Conference. ASCO 2009 Annual Meeting. Orlando, US.
2009. Chronic myeloid leukemia (CML) with e1a2 BCR-ABL fusion transcript type: Analysis of characteristices, outcomes, and prognostic significance. Conference. ASCO 2009 Annual Meeting. Orlando, US.
2009. Tratamiento De Los Sindromes Mielodisplasicos En El 2009, Programa de la XXVII Reunion Anual de la Asociacion Castellano-Leonesa de Hematologia y Hemoterapia. Invited. Asociacion Castellano-Hematologia. Carrion de los Condes, ES.
2008. Making Combination Therapy Reality. Invited. 50th Meeting American Society of Hematology Friday Satellite Symposium Integrating New Developments in MDS in Clinical Practice, US.
2008. Estado actual del manejo de los SMD de alto riesgo. Invited. Evidencia y practica en sindromes mielodisplasias. Barcelona, ES.
2008. Advances In MDS. Invited. Spanish Association of Myelodysplastic Syndromes. Palma de Mallorca, ES.
2008. Practical Case: Treatment Options for a Patient with Acute Myeloid Leukemia in First Remission. Invited. 44th ASCO Annual Meeting. Chicago, US.
2008. Use of HDAC inhibitors alone and in combination with hypomethylating agents. Invited. European School of Haematology, Myelodysplastic Syndromes and Bone Marrow Failure International Conference. Albufeira, PT.
2008. Advances in MDS. Invited. XLIX Congress of the Mexican Society of Hematology, Plenary Session, Dr. Guillermo Ruiz Reyes Lecture. Monterrey, MX.
2008. Hypomethylating Agents in MDS. Invited. State of the Art in Myeloid Malignancies Conference, The University of Texas MD Anderson Cancer Center. Madrid, ES.
2007. Myelodysplastic Syndromes: Modifying the Epigenome as a Therapeutic Strategy in Myelodysplasia. Invited. Friday Satellite Symposium, 49th American Society of Hematology Annual Meeting. Atlanta, US.
2007. i3 CME Satellite Symposia - The Hematology Circle - Rebalancing Molecular Profiles in Hematologic Malignancies: New Technologies for Targeting Silenced and Overexpressed Genes. Invited. Friday Satellite Symposium, 49th American Society of Hematology Annual Meeting. Atlanta, US.
2007. Epigenetic Alterations in Leukaemia. Invited. CNIO Conference, The European School of Oncology. Madrid, ES.
2007. Leukemia Module. Invited. Instituto Nacional de Cancerologia de Mexico and Sociedad Latinoamericana y del Caribe de Oncologia Medica (SLACOM). Cancun, MX.
2007. New Strategies in the Treatment of MDS. Invited. New developments in Hematologic Malignancies. Chicago, US.
2007. Combination epigenetic therapy. Invited. The Ninth International Symposium on Myelodysplastic Syndromes. Florence, IT.
2007. Desarrollo de Epigenetica en Cáncer. Invited. 2do Congreso Internacional de Terapias Biolόgicas en México. Tequesquitengo, MX.
2007. Combination epigenetic therapy in leukemia and MDS. Invited. European Hematology Association Scientific Workshop: The Role of Epigenetics in Hematological Malignancies. Mandelieu, FR.
2007. Advances in the treatment of AML. Invited. First Haematology/Oncology Symposium. Magaliesburg, ZA.
2006. Using combination therapy to improve control: DNA methylation and HDAC inhibition. Invited. 48th Annual Meeting of the American society of Hematology, Friday Satellite Symposium. Orlando, US.
2006. Epigenetic therapy of leukemia. Invited. CNIO Symposium on Molecular Markers in Cancer Therapy. Madrid, ES.
2006. Treatment of MDS. Invited. Portuguese Society of Hematology 2006. Lisbon, PT.
2006. Update on the treatment of MDS. Invited. 32nd Meeting of the Turkish Hematology Association and 1st Meeting of the Balkan Hematology Society. Antalya, TR.
2006. Targeted Therapy for AML. Invited. Recent Advances in AML Biology and Treatment. Barcelona, ES.
2006. Breakthrough in the management of myelodysplastic syndrome. Invited. 36th Annual Meeting of the Philippine Society of Hematology and Blood Transfusion. Mandaluyong, PH.
2006. Disrupting chromatin topology: models for future clinical trails. Invited. Annual Meeting European Hematology Association. Amsterdam, NL.
2006. Papel de las terapias blanco en leucemias. Invited. 1er congreso Nacional de Terapias Biologicas en Mexico, MX.
2005. Aberrant DNA methylation of a cell cycle regulatory pathway composed of p73, p15, and P57kip2 is associated with poor prognosis in adult patients with philadelphia chromosome negative acute lymphocytic leukemia. Invited. 47th Annual Meeting of the American Society of Hematology. Atlanta, US.
2005. Effective use of hypomethylating agents: future directions. Invited. 47th Annual Meeting of the American Society of Hematology. Atlanta, US.
2005. Targeting DNA Hypomethylation. Invited. International Congress of Myeloproliferative Diseases and Myelodysplastic Syndrome. Washington, US.
2005. Clinical experience with hypomethylating agents. Invited. ASCO MGI Industry Sponsored Satellite Symposium. Atlanta, US.
2005. Results of a phase I/II study of the combination of 5-aza-2’-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome. Invited. American Society of Clinical Oncology Annual Meeting. Orlando, US.
2005. Advances in the treatment of Chronic Myelogenous Leukemia. Invited. V Congresso Association Canaria de Hematologica. La Gomera.
2005. Advances in the treatment of Chronic Myelogenous Leukemia. Invited. XXII Reunion de la Socidad Castellano Leonesa de Hematologia y Hemoterapia. Leon, ES.
2004. Advances in the treatments of leukemia. Invited. II Simposio Avances y Nuevas Perspectivas en Linfomas. Valencia, ES.
2003. Advances in Chronic myelogenous leukemia. Invited. XVIII Peruvian Congress of Oncology. Lima, PE.
2003. Tratamiento de la LMC con Imatinib. Invited. IV Congreso De La Asociacion Canaria De Hematologia. La Palma, Canary Islands, ES.
2003. Treatment of chronic myelogenous leukemia with imatinib mesylate. Invited. IV Symposium of the Hematology Society of the Canary Islands (ACAHEM). La Palma, ES.
2003. Novel treatment strategies for hematological malignancies: Epigenetic therapy of leukemia. Invited. I International Oncology Symposium. Madrid, ES.
2000. New treatment strategies for acute myelogenous leukemia. Invited. XVIII Meeting of Castellano-Leones Society of Hematology. Salamanca, ES.
1992. Compounds that induce FRA16B modify the in vitro behavior of DNA-topoisomerase II. Invited. XVII Congress of the European Society of Medical Oncology. Lyon, FR.

2024. Clonal hematopoiesis, myelodysplastic syndromes and cardiac disease. Invited. Houston, TX, US.
2023. MDS at MD Anderson Cancer Center. Invited. Bronx, NY, US.
2023. Academic Life. Invited. Houston, TX, US.
2021. Update on the MDS-AML Moon Shot. Invited. Houston, US.
2021. Myelodysplastic Syndromes. Invited, US.
2021. Case based lecture on Novel agents for LR-MDS. Invited, US.
2020. High Risk Hematology Conference Series: MDS. Invited, US.
2020. Basic Concepts of MDS. Invited, US.
2020. Future Approaches to Treatment of MDS. Invited, US.
2020. Progress in MDS. Invited. Houston, TX, US.
2019. Epigenetic malignant modification, is this reversible?. Invited. Houston, TX, US.
2019. NGS vs flow cytometry, or both? For MRD. Invited. Houston, TX, US.
2019. Breaking MDS. Invited. Besthesda, MD, US.
2019. Fellows' Visiting Professor for 2019 - Deconstructing MDS. Invited. Rochester, MN, US.
2019. Update on Myelodysplastic Syndromes. Invited. Scottsdale, AZ, US.
2019. Pursuing a Career in Oncology. Invited. Houston, TX, US.
2018. Breaking MDS. Invited. New York, NY, US.
2018. Review of MDS clinical trial portfolio at MDACC. Visiting, TX, US.
2018. Molecular Bases Moleculares del Cáncer. Visiting. Madrid, Spain, ES.
2016. Introduction to MDS. Invited. Houston, TX, US.
2014. Leukemia Case Studies. Visiting. Houston, TX, US.
2014. Update on MDS. Visiting. Dallas, TX, US.
2012. Innate Immunity Alterations of MDS. Visiting. Bethesda, MD, US.
2011. Advances in Myelodysplastic Syndromes. Visiting. Houston, TX, US.
2011. Use of Epigenetic Information in Leukemia. Visiting. Houston, TX, US.
2011. The Latest Therapies for MDS. Invited. Cleveland, OH, US.
2011. Molecular Alterations in Myelodysplastic Syndromes. Visiting. Houston, TX, US.
2011. An update on “epigenetic” therapy at MDACC. Visiting. Houston, TX, US.
2010. Highlights from ASH (American Society of Hematology) 2010. Visiting. Houston, TX, US.
2010. MDS: Tailoring Treatment to Optimize Patient Outcomes. Invited. Corpus Christi, TX, US.
2010. Myelodysplastic Syndromes. Visiting. Washington, DC, US.
2010. MDS. Visiting. Houston, TX, US.
2010. Working Groups in Chronic Myelogenous Leukemia: Key Issues in Primary Treatment, Evaluation, and Second-Line Therapy. Visiting, US.
2009. Enhancing (Incorporating) HDACi in leukemia. Invited. St. Louis, MO, US.
2009. MDS: Classification, Genetics and Chromatin. Invited. New York, NY, US.
2009. Hematology/Oncology Educational Series. Visiting. Houston, TX, US.
2009. Hematology Lecture on MDS for DoCM Fellows. Visiting. Houston, TX, US.
2009. Update in MDS. Invited. Bilbao, ES.
2008. Progress in MDS. Invited. Milwaukee, WI, US.
2008. Progress in MDS. Invited. Milwaukee, WI, US.
2008. Progress in MDS. Invited. Boston, MA, US.
2008. Using Epigenetic Information in Leukemia. Invited. Aurora, CO, US.
2008. Progress in MDS. Invited. Lawson, OK, US.
2008. Management of Myelodysplasia at MD Anderson. Visiting. Houston, TX, US.
2008. Incorporating epigenetic information in leukemia care. Invited. Tampa, FL, US.
2008. Update on MDS. Invited. New Orleans, LA, US.
2008. Combination Epigenetic Therapy. Visiting. Houston, TX, US.
2008. Some more on the epigenetics of leukemia. Visiting. Houston, TX, US.
2008. Using epigenetic information in leukemia. Visiting. Houston, TX, US.
2008. Targeting Chromatin in Hematologic Malignancies. Invited. Atlanta, GA, US.
2008. Advances in MDS. Invited. Orlando, FL, US.
2008. An approach to the treatment of MDS. Visiting. Philadelphia, PA, US.
2008. Advances in MDS. Invited. Mobile, AL, US.
2008. Myelodysplastic Syndromes. Visiting. Houston, TX, US.
2007. Epigenetic therapy of leukemia. Invited. Baltimore, MD, US.
2007. Update on MDS at The University of Texas MD Anderson Cancer Center. Invited. Sevilla, ES.
2007. Update on treatment of MDS and CML management. Invited. Philadelphia, PA, US.
2007. Update on Treatment of MDS. Visiting. Philadelphia, PA, US.
2007. Current Treatments for MDS. Invited. Tucson, AZ, US.
2007. Current Treatments for MDS. Visiting. Dallas, TX, US.
2007. MDS Updates. Invited. Seattle, WA, US.
2007. Manipulating epigenetic repression in leukemia. Visiting. Houston, TX, US.
2007. Myelodysplastic Syndrome. Visiting. Houston, TX, US.
2007. Current Treatments for MDS. Invited. Albuquerque, NM, US.
2007. The MDS Program. Visiting. Houston, TX, US.
2007. Estado actual del tratamiento de los sindromes mielodisplasicos. Invited. Son Dureta Palma Mallorca, ES.
2007. Update in the management of myelodysplastic syndrome. Visiting. Corpus Christi, TX, US.
2007. Update in the management of myelodysplastic syndrome. Visiting. Corpus Christi, TX, US.
2007. Treatment update on MDS. Invited. Englewood, CO, US.
2007. Treatment update on MDS. Invited. Provo, UT, US.
2007. Advances in the treatment of MDS. Invited. Columbus, GA, US.
2007. Treatment of MDS. Visiting. Houston, TX, US.
2007. Advances in the Treatment of MDS. Invited. Lexington, KY, US.
2007. Current treatment options for myelodysplastic syndromes. Invited. Louisville, KY, US.
2007. Clinical development of histone deacetylase inhibitors. Invited. Antwerp, BE.
2007. Advances in MDS. Invited. St. Louis, MO, US.
2007. Advances in MDS. Invited. St. Louis, MO, US.
2007. Epigenetic Therapy of Leukemia. Invited. Charleston, SC, US.
2007. Epigenetic therapy of leukemia. Visiting. Durham, NC, US.
2006. Update on myelodysplastic syndrome. Invited. Houston, TX, US.
2006. Update on myelodysplastic syndrome. Visiting. Houston, TX, US.
2006. Update on MDS. Invited. Dallas, TX, US.
2006. Epigenetic changes in leukemia. Visiting. Houston, TX, US.
2006. Epigenetic Therapy of Leukemia/MDS. Invited. St. Louis, MO, US.
2006. Advances in the Treatment of MDS. Invited. Kansas City, MO, US.
2006. Current treatment options for myelodysplastic syndromes. Invited. Charleston, WV, US.
2006. Implications of aberrant DNA methylation in acute lymphocytic leukemia. Invited. Lexington, KY, US.
2006. Clinical experience with hypomethylating agents. Visiting. Baltimore, MD, US.
2006. Epigenetic alterations in leukemia: prognostic and therapeutic implications. Invited. Harvey, IL, US.
2006. The role of epigenetic therapeutics in hematological malignancies. Invited. Marquette, MI, US.
2006. HDAC's and leukemia. Visiting. Houston, TX, US.
2006. Implications of epigenetic information in leukemia. Invited. Chicago, IL, US.
2005. Introduction to MDS. Visiting. Houston, TX, US.
2005. Treatment of myelodysplastic syndrome. Invited. Chicago, IL, US.
2005. Implementing epigenetic information in the treatment and prognosis of patients with leukemia. Invited. Milwaukee, WI, US.
2005. Implementing epigenetic information in the treatment and prognosis of patients with leukemia. Visiting. Madison, WI, US.
2005. Use of 5-azacytidine in myelodysplastic syndrome. Visiting. Shreveport, LA, US.
2005. New approaches to the treatment of the acute lymphocytic leukemia. Invited. Atlanta, GA, US.
2005. New approaches to the treatment of the acute lymphocytic leukemia. Invited. Charleston, SC, US.
2005. Advances in Chronic Myelogenous Leukemia. Invited. West Palm Beach, FL, US.
2005. New approaches to the treatment of the acute lymphocytic leukemia. Invited. Durham, NC, US.
2004. Advances in Acute Lymphocytic Leukemia. Invited. Santa Fe, NM, US.
2004. JunB expression in CML. Visiting. Houston, TX, US.
2004. An epigenetic approach to the treatment and prognosis of patients with leukemia. Visiting. Philadelphia, PA, US.
2004. An approach to the patient with MDS. Invited. West Palm Beach, FL, US.
2004. p57KIP2 expression as a prognostic marker in adult ALL. Visiting. Houston, TX, US.
2004. Molecular pathogenesis of ALL. Visiting. Houston, TX, US.
2004. Acetylation Properties of Valproic Acid. Visiting. Houston, TX, US.
2004. Epigenetic Alterations in Leukemia: Prognostic and Therapeutic Implications. Visiting. New York, NY, US.
2004. Epigenetic therapy in leukemia. Visiting. Houston, TX, US.
2004. New Advances in the Treatment of CML. Invited. Albuquerque, NM, US.
2003. Advances in the Treatment of Chronic Myelogenous Leukemia. Invited. Enid, OK, US.
2003. Epigenetic alterations in leukemia. Invited. Barcelona, ES.
2003. Azacitidine. Visiting. Houston, TX, US.
2003. Hypomethylating agents. Visiting. Houston, TX, US.
2003. Epigenetic alterations in leukemia: clinical implications. Visiting. Houston, TX, US.
2003. Mortality Cases. Visiting. Houston, TX, US.
2003. Epigenetic therapy of leukemia. Invited. Pamplona, ES.
2002. DNA methylation in hematological malignancies: clinical implications. Invited. Palma de Mallorca, ES.
2002. Molecular Epigenetics of Leukemia: clinical implications. Visiting. Houston, TX, US.
2002. Advances in Leukemia. Invited. Enid, OK, US.
2002. Phase I Study of Dose Escalation Idarubicin with Amifostine and High-Dose ara-C. Visiting. Houston, TX, US.
2002. Phase I Study of Dose Escalation Idarubicin with Amifostine and High-Dose ara-C. Visiting. Houston, TX, US.
2002. Leukemia, lymphoma and multiple myeloma. Visiting. Houston, TX, US.
2001. Aberrant methylation in acute leukemia: Therapeutic implications. Visiting. Houston, TX, US.
2001. DNA-methylation in lymphoid malignancies. Visiting. Houston, TX, US.
2001. Aberrant methylation in acute leukemia: Therapeutic implications. Visiting. Houston, TX, US.
2001. Aberrant DNA methylation in pediatric and adult ALL. Visiting. Houston, TX, US.
2001. DNA methylation in acute lymphocytic leukemia. Invited. Philadelphia, PA, US.
2001. Treatment alternatives for patients with chronic phase CML. Invited. Philadelphia, PA, US.
2000. An Overview of Breast Cancer from the Oncologist's Perspective. Visiting. Houston, TX, US.
2000. Cancer of the Prostate. Visiting. Houston, TX, US.
1998. Acute myelogenous leukemia. Immunotherapy and Cytoprotection. Invited. Winston-Salem, NC, US.

Less

Grant & Contract Support

Date:	2025 - 2028
Title:	Therapeutically overcoming transfusion-dependency in myelodysplastic syndromes with ringed sideroblasts
Funding Source:	NCI
Role:	PI
ID:	GRANT14347290

Date:	2025 - 2028
Title:	Targeting nucleoside metabolism and anti-apoptotic mechanisms in high risk CMML
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I

Date:	2025 - 2025
Title:	Targeting MEK and FAK signaling in high risk RAS-mutant chronic myelomonocytic leukemia
Funding Source:	Elsa Pardee Foundation
Role:	Co-I

Date:	2024 - 2026
Title:	ENHANCEMENT OF HIGH-DOSE CHEMOTHERAPY FOR REFRACTORY LYMPHOMAS THROUGH PARP INHIBITION
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2024 - 2029
Title:	Therapeutic targeting of immune evasion and inflammatory pathways to prevent myelodysplastic syndrome initiation and progression
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Date:	2024 - 2029
Title:	Therapeutic targeting of immune evasion and inflammatory pathways to prevent myelodysplastic syndrome initiation and progression
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Date:	2024 - 2029
Title:	Targeting NK cell dysfunctions to overcome immune escape in early stage myelodysplastic syndromes
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2024 - 2027
Title:	Genomic Expert Curation Panel for FLT3 alterations in Hematological Malignancies
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2024 - 2028
Title:	2022-1080 A Pilot, Open-Label Study of Luspatercept for Patients with Lower Risk Myelodysplastic Syndromes (MDS)
Funding Source:	BMS
Role:	PI

Date:	2023 - 2026
Title:	A Phase 1b/2a Trial of the Anti-IL1RAP Antibody Nadunolimab in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	GRANT13706546

Date:	2023 - 2025
Title:	Developing an inhibitor of EIF2AK1 to overcome ineffective erythropoiesis in myelodysplastic syndromes with ringed sideroblasts
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2023 - 2026
Title:	Targeting the EIF2AK1 signaling pathway to overcome ineffective erythropoiesis in myelodysplastic syndrome with ringed sideroblasts (MDS-RS) and SF3B1 mutations
Funding Source:	Evans MDS Foundation
Role:	Co-I

Date:	2023 - 2026
Title:	2022-0179 A phase 1b, open label, multi-center, dose optimization and dose expansion study to assess the safety and efficacy of DFV890 in adult patients with myeloid diseases Project Goal: To assess the safety, tolerability, pharmacokinetics (PK). pharmacodynamics (PD), efficacy and recommended dose (RD) for single agent (SA) DFV890
Funding Source:	Novartis
Role:	PI

Date:	2023 - 2030
Title:	2023-0020 Phase ½ Multicenter, Open-Label Study of CTX-712 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Funding Source:	Chordia Therapeutics, Inc
Role:	PI

Date:	2023 - 2026
Title:	Targeting anti-poptotic pathways in MDS patients with refractory disease
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2023 - 2026
Title:	2022-0595 A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia
Funding Source:	K Group Alpha
Role:	PI

Date:	2023 - 2026
Title:	2022-0701 A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Doubleblind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Funding Source:	Celgene
Role:	PI

Date:	2022 - 2027
Title:	Specialized Center of Research: An Integrated Approach towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Date:	2022 - 2025
Title:	Characterizing clonal evolution in MDS patients with HMA failure using longitudinal sequencing data and novel computational methods
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I

Date:	2022 - 2027
Title:	Clinical Validation of Predictive Biomarkers of Response to Venetoclax-Based Therapy in Patients with Myelodysplatic Syndromes at the Time of Progression after Therapy with Hypomethylating Agents
Funding Source:	NIH/NCI
Role:	Collaborator

Date:	2022 - 2026
Title:	2022-0186 An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS) Who are Refractory/Resistant to Prior Therapies
Funding Source:	Rigel Pharmaceuticals
Role:	PI

Date:	2022 - 2025
Title:	An Integrated Approach towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes (MRP)
Funding Source:	MD Anderson
Role:	PI

Date:	2022 - 2026
Title:	2021-0110: Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator’s choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multicenter) (STIMULUS MDS-US)
Funding Source:	Novartis
Role:	PI

Date:	2022 - 2026
Title:	2020-0895: Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination with Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes
Funding Source:	Stemline Therapeutics
Role:	Co-PI

Date:	2022 - 2025
Title:	2021-0601 A Single-Arm, Open-Label, Phase II Study of Sabatolimab In Combination with Azacitidine and Venetoclax In Adult Participants with High or Very High Risk Myelodysplastic Syndrome (MDS) As Per IPSS-R Criteria
Funding Source:	Novartis
Role:	PI

Date:	2021 - 2024
Title:	Targeting IL1 beta in clonal cytopenia of undetermined significance and low risk myelodysplastic syndrome
Funding Source:	Edward P. Evans Foundation
Role:	PI

Date:	2021 - 2025
Title:	2020-1117: Phase I Study of Fostamatinib, a SYK inhibitor, in patients with Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia who have failed therapy with Hypomethylating Agents
Funding Source:	Rigel Pharmaceuticals
Role:	Co-PI

Date:	2021 - 2025
Title:	2021-0144: A Phase 1/2 study of ALX148 in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML) (ASPEN-05)
Funding Source:	ALX Oncology
Role:	PI

Date:	2021 - 2025
Title:	2021-0497: A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications
Funding Source:	Karopharma
Role:	PI

Date:	2021 - 2025
Title:	2020-0487: Phase I/II Study of SP-2577 (Seclidemstat) in Combination with Azacitidine for patients with Myelodysplastic syndromes and Chronic Myelomonocytic Leukemia
Funding Source:	Salarius Pharmaceuticals LLC
Role:	Co-PI

Date:	2021 - 2025
Title:	2020-0983: A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
Funding Source:	Incyte
Role:	PI

Date:	2021 - 2025
Title:	2020-0183: A Phase Ib, Multicenter, Open-Label Platform Study of Select Drug Combinations in Adult Patients with Lower Risk (very low, low, or intermediate risk) Myelodysplastic Syndrome
Funding Source:	Novartis
Role:	PI

Date:	2021 - 2025
Title:	2020-1119: Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination with Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes
Funding Source:	Aprea Therapeutics
Role:	PI

Date:	2021 - 2025
Title:	Astex Alliance Projects
Funding Source:	Astex
Role:	PI

Date:	2020 - 2025
Title:	2020-0030: A phase II, multicenter, single arm safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy
Funding Source:	Novartis
Role:	PI

Date:	2020 - 2025
Title:	2020-0180: A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Funding Source:	Abbvie
Role:	PI

Date:	2020 - 2025
Title:	2020-0129 ML42088 A phase I/II study of venetoclax in combination with ASTX727 (cedazuridine/decitabine) in treatment-naïve high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)
Funding Source:	Genentech Inc
Role:	PI

Date:	2020 - 2023
Title:	2020-0615: A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Funding Source:	Seattle Genetics
Role:	PI

Date:	2020 - 2025
Title:	2020-0572 AT148002 A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS)
Funding Source:	ALX Oncology
Role:	PI

Date:	2020 - 2025
Title:	2020-0546 ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome
Funding Source:	Forty Seven Inc
Role:	PI

Date:	2020 - 2025
Title:	2019-1178: Phase I/II Study of Azacitidine in Combination with Quizartinib for patients with Myelodysplastic syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL mutations
Funding Source:	Daiichi Sankyo, Inc
Role:	Co-I

Date:	2020 - 2025
Title:	2020-0128: STRATEGIC ALLIANCE: 2020-0128 ML42089 A phase I/II study of venetoclax in combination with ASTX727 (cedazuridine/decitabine) in treatment-naive high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)
Funding Source:	Genentech Inc
Role:	PI

Date:	2020 - 2025
Title:	2020-0025: Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with (MDS), (CMML), or (AML)
Funding Source:	Astex Pharmaceuticals
Role:	PI

Date:	2020 - 2025
Title:	2019-1246: A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Funding Source:	Curis
Role:	PI

Date:	2019 - 2022
Title:	2019-0760: Phase I Study of APR-246 in Combination with Venetoclax and Azacitidine in TP53 Mutant Myeloid Malignancies
Funding Source:	Aprea Therapeutics
Role:	PI

Date:	2019 - 2022
Title:	2019-0340: A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, am Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers
Funding Source:	Janssem Research and Development, LLC
Role:	PI

Date:	2019 - 2026
Title:	2019-0339: A Phase II, Open-Label, Study of Subcutaneous canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients with Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Funding Source:	Novartis
Role:	PI

Date:	2019 - 2026
Title:	2019-0126: A Phase 3B, Open-Label, Single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials
Funding Source:	Celgene
Role:	PI

Date:	2019 - 2026
Title:	RNA mutations in human cancers
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2019 - 2021
Title:	Dissecting pathogenic cooperation between KDM6B overexpression and TET2 loss in bone marrow failure
Funding Source:	Department of Defense (DOD)
Role:	PI

Date:	2019 - 2026
Title:	2019-0400: ASTX727-06: An Open-Label. Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Funding Source:	Astex Pharmaceuticals
Role:	PI

Date:	2019 - 2025
Title:	2019-0368: Phase I/II of Venetoclax in combination with Azacitidine in treatment naive and relapse refractory high risk MDS individuals
Funding Source:	Abbvie/Genentech
Role:	PI

Date:	2019 - 2025
Title:	2018-0911: Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents
Funding Source:	Jazz Pharmaceuticals, Inc
Role:	Co-I

Date:	2019 - 2026
Title:	2018-0179: A Phase 3, Open-Label, Random Study to Compare the Efficacy and Safety of Luspatercept (ACE 536) vs Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low, or Immediate Risk (MDS) in ESA Naive Subjects who require RBC Transfusions
Funding Source:	Celgene
Role:	PI

Date:	2019 - 2026
Title:	2018-0919: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate 1) Myelodysplastic Syndromes (MDS)
Funding Source:	Astex Pharmaceuticals
Role:	PI

Date:	2019 - 2023
Title:	Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	R01CA235622

Date:	2018 - 2022
Title:	2018-0912: A Phase II Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes
Funding Source:	Aprea Therapeutics
Role:	PI

Date:	2018 - 2019
Title:	NO TITLE PROVIDED
Funding Source:	UTMDACC Leukemia SPORE Development Award
Role:	Collaborator

Date:	2018 - 2023
Title:	Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	R01CA235622

Date:	2018 - 2025
Title:	2018-0309: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Funding Source:	H. Lee Moffitt Cancer Center
Role:	PI

Date:	2018 - 2025
Title:	2018-0309: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Funding Source:	Aprea Therapeutics
Role:	PI

Date:	2018 - 2020
Title:	Preventing therapy-related leukemia and myelodysplastic syndromes
Funding Source:	NIH/NCI
Role:	PI
ID:	1 R21 CA226203

Date:	2018 - 2021
Title:	2018-0009: A Phase 1, Multicenter, open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients with Intermediate or High-Risk Myelodysplastic Syndrome
Funding Source:	Amphivena Therapeutics
Role:	PI

Date:	2018 - 2021
Title:	Preventing therapy-related leukemia and myelodysplastic syndromes in Texas
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP180583

Date:	2018 - 2023
Title:	2017-0887: F/U to the Open Label Phase I/II study OPN-305-106 (A Prospective, Open Label Phase I/II to assess Safety & Efficacy of Cycles of IV Infused OPN-305 in Second-line and First-line lower (Low and intermediate-1) risk (MDS))
Funding Source:	Opsona Therapeutics Ltd
Role:	PI

Date:	2017 - 2021
Title:	2017-0886: A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Funding Source:	Astex Pharmaceuticals
Role:	PI

Date:	2017 - 2021
Title:	2017-0173: A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients 18 Years with Newly Diagnosed Acute Myeloid Leukemia Unfit for Standard Induction Chemotherapy
Funding Source:	Helsinn Healthcare
Role:	PI

Date:	2017 - 2021
Title:	2016-0944: A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure
Funding Source:	AbbVie
Role:	PI
ID:	54170

Date:	2017 - 2019
Title:	Mechanisms of natural killer (NK) cell immune escape in mylodysplastic syndromes
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R21 CA222037-01

Date:	2017 - 2023
Title:	Targeting IRAK 1/4 in Myelodysplastic Syndromes
Funding Source:	NIH/NIDDK
Role:	Principal Investigator-MDACC
ID:	R01 DK113639

Date:	2017 - 2025
Title:	2014-0930: Combination of nivolumab and ipilimumab with 5-azacitidine in patients with myelodysplastic syndromes (MDS)
Funding Source:	Bristol Myers Squibb
Role:	PI
ID:	3130

Date:	2017 - 2020
Title:	2016-0974: ' Phase I/II, open-label, 2 arm study to investigate the safety, clinical activity, pharmacokinetics, and pharmacodynamics of GSK2879552 administered alone or in combination with azacitidine, in adult subjects with IPSS-R high and very high risk myelodysplastic syndromes (MDS) previous treated with hypomethylating agents (HMA)
Funding Source:	GlaxoSmithKline
Role:	PI
ID:	13029044

Date:	2017 - 2025
Title:	2016-0757: To assess and compare overall survival (OS) between guadecitabine and treatment choice (TC) in adults with
Funding Source:	Abbvie
Role:	PI
ID:	53682

Date:	2017 - 2020
Title:	2016-0969: A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) who are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Funding Source:	Janssen Research and Development LLC
Role:	PI
ID:	54008

Date:	2017 - 2024
Title:	2016-0343: A phase II study of the combination of azacitidine and pembrolizumab for patients with MDS
Funding Source:	Merck and Company
Role:	PI
ID:	13028436

Date:	2017 - 2025
Title:	2017-0256: Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome
Funding Source:	Novartis
Role:	PI

Date:	2017 - 2022
Title:	2016-0587: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents
Funding Source:	Astex Pharmaceuticals, Inc
Role:	PI
ID:	53402

Date:	2016 - 2021
Title:	2016-0182: A Randomized Multi-center,Open-label, Phase 2 Study evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination w/(MEDI4736) in Previously Untreated Subjects w/Higher Risk MDS or in Elderly AML Subjects Not Eligible (HSCT)
Funding Source:	Celgene
Role:	PI
ID:	52461

Date:	2016 - 2019
Title:	Clonal hematopoiesis as a predictive biomarker for the development of thrapy-related myeloid neoplasms
Funding Source:	EvansMDS Foundation
Role:	PI

Date:	2016 - 2018
Title:	Decitabine and dCTPase inhibitor combination: proof-of-concept studies in MDS
Funding Source:	The University of Texas MD Anderson Cancer Center Sister Institute Network Fund
Role:	PI

Date:	2016 - 2019
Title:	2015-0979: A phase 3,double-blind,randomized study to compare the efficacy & safety of luspatercept (ACE-536) vs. placebo for the treatment of anemia due to ipss-r very low,or intermediate risk MDS in subjects w/ ring sideroblast
Funding Source:	Celgene Corporation
Role:	PI
ID:	CS2016-00051933

Date:	2016 - 2017
Title:	2015-0297: A Phase 1b Study of the Safety and Pharmacology of MPDL3280A (Anti PDL-1 antibody) Administered Alone or in Combination with Azacitidine in Patients with Myelodysplastic Syndromes
Funding Source:	Genentech
Role:	PI
ID:	CS2015-13015361

Date:	2016 - 2023
Title:	Therapeutic targeting of glutamine metabolism in MDS
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01CA206210

Date:	2016 - 2022
Title:	2016-0547: An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Funding Source:	H3 Biomedicine, Inc
Role:	PI

Date:	2016 - 2019
Title:	2015-0984: A Phase 1/2 Study of Vadastuximab Talrine (SGN-CD33A) in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Funding Source:	Seattle Genetics
Role:	PI
ID:	52001

Date:	2015 - 2024
Title:	2014-0934: Phase II combination of lirilumab and nivolumab with 5-azacitidine in patients with myelodysplastic syndromes (MDS)
Funding Source:	Bristol Myers Squibb
Role:	PI
ID:	3132

Date:	2015 - 2024
Title:	2015-0617: A phase 2, open-label, single-arm rollover study to evaluate long-term safety in subjects who participated in other Celgene sponsored CC-486 (oral azacitidine) clinical trials in solid tumors and hematological disorders
Funding Source:	Celgene Corporation
Role:	PI
ID:	3565

Date:	2015 - 2021
Title:	2015-0360: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
Funding Source:	Onconova Therapeutics
Role:	PI
ID:	3360

Date:	2015 - 2020
Title:	2015-0516: A Phase 1 Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 in Patients with Relapsed Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Funding Source:	Forma Therapeutics
Role:	PI
ID:	3379

Date:	2015 - 2021
Title:	2015-0056: A Phase 2, International, Multicenter, Single-Arm, Open-Label Study To Evaluate The Efficacy And Safety Of CC-486 (Oral Azacitidine) In Subjects With Myelodysplastic Syndromes Who Fail To Achieve An Objective Response To Treatment w Azacitidine for injection or decitabine
Funding Source:	Celgene
Role:	PI
ID:	3087

Date:	2015 - 2017
Title:	Stromal Interactions and Leukemic Risk in Myelodysplastic Syndromes
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R21 CA195689-01

Date:	2014 - 2018
Title:	2014-0432: A Prospective, Open Label Phase I/II Study To Assess The Safety And Efficacy Of Cycles Of Intravenously Infused Doses Of OPN-305 In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS)
Funding Source:	Opsona Therapeutics
Role:	PI
ID:	12248

Date:	2014 - 2016
Title:	Blocking Innate Immune Signaling: Toward New Treatments for Myelodysplastic Syndromes
Funding Source:	Golfers Against Cancer
Role:	PI

Date:	2014 - 2018
Title:	2014-0391: Phase 1/2 Dose-Escalation, Safety, Clinical Activity, Pharmacokinetic and Pharmacodynamic Study Of The ERK 1/2 Inhibitor BVD-523 In Patients With Acute Myelogenous Leukemia Or Myelodysplastic Syndromes
Funding Source:	BioMed Valley
Role:	PI
ID:	12067

Date:	2014 - 2024
Title:	2013-0901: Phase 2 Study of SGI-110 in Patients with Higher Risk MDS
Funding Source:	Astex
Role:	PI
ID:	11009

Date:	2014 - 2019
Title:	2014-0451: An Open-label Rollover Study to Continue ARRY-614 Treatment in Patients Previously Treated With ARRY-614 in Clinical Studies Sponsored by Array BioPharma Inc
Funding Source:	Array Biopharma
Role:	PI
ID:	12757

Date:	2014 - 2017
Title:	Targeting immune checkpoints in hypomethylating failure
Funding Source:	Leukemia and Lymphoma Society
Role:	PI
ID:	LLS TRP

Date:	2014 - 2017
Title:	Targeting Toll-like Receptor and innate immunity signaling in hypomethylating failure MDS
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-I
ID:	LLS TRP

Date:	2014 - 2018
Title:	Towards the cure of myelodysplastic syndrome: interfering with innate immunity alterations in human and mouse systems
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP140500

Date:	2014 - 2017
Title:	Molecular pathogenesis of MDS
Funding Source:	NIH/NIDDK
Role:	Co-I
ID:	5R01DK102759-02

Date:	2014 - 2019
Title:	2014-0014: A Phase 1/2a, Dose-Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies
Funding Source:	FujiFilm
Role:	PI
ID:	11582

Date:	2014 - 2020
Title:	2014-0089: A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)
Funding Source:	Astex Therapeutics
Role:	PI
ID:	11274

Date:	2014 - 2016
Title:	Targeting Toll-like Receptor and innate immunity signaling in hypomethylating failure MDS
Funding Source:	Aplastic Anemia and MDS International Foundation
Role:	PI

Date:	2014 - 2016
Title:	Targeting immune checkpoints in hypomethylating failure myelodysplastic syndromes
Funding Source:	Aplastic Anemia and MDS International Foundation
Role:	PI

Date:	2014 - 2016
Title:	An Observational Study on Symptoms and Health-Related Quality of Life of Patients with Myelodysplastic Syndromes
Funding Source:	Aplastic Anemia and MDS International Foundation
Role:	Collaborator

Date:	2014 - 2020
Title:	2013-1041: A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
Funding Source:	MedImmune
Role:	PI
ID:	13850

Date:	2014 - 2015
Title:	PA14-0131: Anti-leukemia effect of the combination of inosine monophosphate dehydrogenase (IMPDH)
Funding Source:	FujiFilm Corporation
Role:	PI

Date:	2014 - 2019
Title:	Biology of MDS
Funding Source:	NIH/NHLBI
Role:	PI
ID:	1P01HL117793-01

Date:	2014 - 2018
Title:	2013-0596: A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination with Azacitidine in Elderly (Age > or equal 65 Years) Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Funding Source:	MEI Pharma, Inc
Role:	PI

Date:	2014 - 2020
Title:	2013-0012: Phase I Study of Ruxolitinib for Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
Funding Source:	Incyte Corporation
Role:	PI
ID:	INCB0018424

Date:	2014 - 2015
Title:	2013-0873: A Phase II Simon Two‐Stage of the Addition of Pracinostat to a Hypermethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Funding Source:	MEI Pharma, Inc
Role:	PI
ID:	MDS 15

Date:	2014 - 2019
Title:	Identification and characterization of targets for BiTE therapy in Myelodysplastic Syndrome
Funding Source:	Amgen
Role:	PI

Date:	2014 - 2016
Title:	Overcoming resistance to hypomethylating agents in myelodysplastic syndromes
Funding Source:	Fundacion Ramon Areces
Role:	PI

Date:	2013 - 2020
Title:	2013-0531: A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies
Funding Source:	Merck, Sharp & Dohme Corporation
Role:	PI
ID:	MK-3475-013-00

Date:	2013 - 2016
Title:	Role of deregulated innate immuinity signaling in resistance to hypomethylating agent based therapy in myelodysplastic syndrome and acute myelogenous leukemia
Funding Source:	Gabrielle's Angel Foundation
Role:	Mentor

Date:	2013 - 2025
Title:	MDS/AML Moon Shot
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2013 - 2016
Title:	2012-0562: Phase II Study of Subcutaneous Bortezomib for Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
Funding Source:	Millennium Pharmaceuticals, Inc
Role:	PI

Date:	2013 - 2017
Title:	2013-0321: A Phase II Randomized, Double-Blinded, Placebo-Controlled Study of Pracinostat in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk 2 or High-Risk Myelodysplastic Syndrome (MDS)
Funding Source:	MEI Pharma, Inc
Role:	PI
ID:	9566

Date:	2013 - 2021
Title:	2013-0030: Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Funding Source:	Onconova Therapeutics
Role:	PI
ID:	8322

Date:	2013 - 2018
Title:	MDS Clinical Research Consortium
Funding Source:	Aplastic Anemia & MDS International Foundation supported by the Evans Foundation
Role:	PI

Date:	2013 - 2015
Title:	2013-0324: Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing On or After Azacitidine or Decitabine
Funding Source:	Onconova Therapeutics
Role:	PI
ID:	8357

Date:	2013 - 2018
Title:	S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (1A) Versus 1A with Vorinostat (NSC‐701852) (1A+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Funding Source:	NIH/NCI
Role:	PI
ID:	26681

Date:	2013 - 2017
Title:	2012-0374: Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Refractory Patients with Leukemias Involving Translocations of the MLL
Funding Source:	Epizyme, Inc
Role:	PI
ID:	CS2012-00037037LG

Date:	2013 - 2016
Title:	Targeting the histone demethylase JMJD3 and innate immunity deregulation in myelodysplastic syndromes
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP130080

Date:	2013 - 2014
Title:	A randomized clinical trial for patients with AML/MDS not fit for chemotherapy
Funding Source:	American Society of Hematology (ASH)
Role:	PI

Date:	2013 - 2018
Title:	Innate Immunity Alterations in MDS
Funding Source:	NIH/NHLBI
Role:	PI
ID:	1R01HL118107-01

Date:	2012 - 2019
Title:	2012-0428: An Open-Label Randomized, Phase 2, Parallel Dose-Ranging Study of Sotatercept (ACE 011) for Treatment of Patients with Anemia and low or intermediate-1 risk MDS
Funding Source:	Celgene Corporation
Role:	PI
ID:	4005.31592C

Date:	2012 - 2020
Title:	2012-0733: A Phase 3, Multicenter, Randomized, Double Blind Study to Compare the Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Placebo plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia due to IPSS Lower-Risk Myelodysplastic Syndromes
Funding Source:	Celgene Corporation
Role:	PI
ID:	4005.31987C

Date:	2012 - 2015
Title:	Targeting of an innate immunity-like pathway in myelodysplastic syndrome
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Date:	2012 - 2015
Title:	CA110791: Innate immunity dysregulation in myelodysplastic syndromes
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	W81XWH-12-1-0221

Date:	2012 - 2015
Title:	A randomized clinical trial for patients with AML/MDS not fit for Chemotherapy
Funding Source:	NIH/NCI
Role:	PI
ID:	GRANT10976413

Date:	2012 - 2014
Title:	Targeting innate immunity alterations in myelodysplastic syndrome (PQ20)
Funding Source:	NIH/NCI
Role:	PI
ID:	R21 000000-00

Date:	2012 - 2013
Title:	Preclinical modeling of OPN-305 in human myelodysplastic syndromes and acute myelogenous leukemia
Funding Source:	Opsona Therapeutics
Role:	PI
ID:	CS2012-00036766RG

Date:	2011 - 2015
Title:	2011-0827: A Phase 1 Study of ARRY-614 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Funding Source:	Array Biopharma, Inc
Role:	PI
ID:	CS2011-00035833

Date:	2011 - 2012
Title:	2011-0548: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International -1-Risk Myelodysplastic Syndrome
Funding Source:	Johnson & Johnson
Role:	PI
ID:	CS2011-00035516JW

Date:	2011 - 2014
Title:	Treating patients with AML/MDS that do not qualify for clinical trials
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Date:	2011 - 2014
Title:	Modulation of IL-6 signaling in myelodysplastic syndromes (MDS)
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-PI

Date:	2011 - 2013
Title:	2011-0427: Phase II Study of SB1518 for Patients with Myelodysplastic Syndrome
Funding Source:	S*BIO Pte Ltd
Role:	PI
ID:	CS2011-00035304JW

Date:	2011 - 2016
Title:	Aberrant DNA Methylation as a Mechanism of Resistance in ALL
Funding Source:	NIH/NCI
Role:	PI
ID:	1 R01 CA161019-01A1

Date:	2011 - 2014
Title:	2010-0317: A Phase 1 Trial of PF-03084014 in Patients with Advanced Solid Tumor Malignancy and T-Cell Acute Lymphoblastic Leukemia
Funding Source:	Pfizer
Role:	PI
ID:	CS2010-32969

Date:	2011 - 2013
Title:	DR09-0074: Amgen Project 2010
Funding Source:	Amgen, Inc
Role:	PI
ID:	CS2011-00033861LG

Date:	2011 - 2016
Title:	2010-0965: Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of PM01183 in Patients with Advanced Acute Leukemia
Funding Source:	PharmaMar USA, Inc
Role:	PI
ID:	CS2011-00034740JW

Date:	2010 - 2016
Title:	2010-0209: A Phase II/III, Randomized Controlled Study to Assess the Efficacy and Safety of ON 01910. Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blast Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine
Funding Source:	Onconova Therapeutics
Role:	PI
ID:	CS2010-00032168MA

Date:	2010 - 2015
Title:	Targeting Microenvironment-Related Resistance in adult acute lymphoblastic leukemia (ALL)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI
ID:	RP101320

Date:	2010 - 2014
Title:	2009-1001: A Phase 3, Multicenter, Randomized, Open-Label Study of Azacitidine (Vidaza) Versus Conventional Care Regimens for the Treatment of Older Subjects with Newly Diagnosed Acute Myeloid Leukemia
Funding Source:	Celgene
Role:	PI
ID:	CS2010-00032590LG 01

Date:	2010 - 2015
Title:	2009-0737: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Placebo in Subjects with Transfusion-Dependent Anemia due to IPSS Low or Intermediate-1 Risk
Funding Source:	Celgene
Role:	PI
ID:	CS2010-00031288LG

Date:	2010 - 2015
Title:	Research Training in Academic Medical Oncology
Funding Source:	NIH/NCI
Role:	Faculty Mentor
ID:	5T32CA009666-17

Date:	2010 - 2013
Title:	Analysis of histone code alterations and JMJD3 using CHIP-seq in myelodysplastic syndromes
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP100202

Date:	2010 - 2013
Title:	2009-0788: A Phase 1 study evaluating the safety and pharmacokinetics of ABT-348 in subjects with Advanced Hematologic Malignancies
Funding Source:	Abbott
Role:	PI
ID:	CS2010-00031401JW 01

Date:	2010 - 2013
Title:	Correlative Study for "A phase I/b, open-label, multi-center, dose-escalation study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML)" 2009-0619
Funding Source:	Novartis
Role:	PI
ID:	LS2010-00031095JW

Date:	2010 - 2012
Title:	2009-0965: Phase I Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra, TLK199 Tablets) In Combination with Lenalidomide (Revlimid) In Patients with Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Funding Source:	Telik
Role:	PI
ID:	CS2010-00031402MA

Date:	2010 - 2016
Title:	2009-0619: A phase I/b, open-label, multi-center, dose-escalation study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML)
Funding Source:	Novartis
Role:	PI
ID:	CS2010-00029764JW 01

Date:	2009 - 2014
Title:	2009-0467: Phase I/II CT Study of the Combination of 5-azacitidine with Lenalidomide in patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Funding Source:	Celgene
Role:	PI
ID:	CS2009-00029597MA

Date:	2009 - 2014
Title:	2010-0041: A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1risk) and transfusional iron overload (TELESTO)
Funding Source:	Novartis
Role:	PI
ID:	CS2010-00031986MA

Date:	2009 - 2012
Title:	2010-0591: A phase 1b CT, dose-finding study of oral panobinostat (LBH589) in combination with idarubicin and cytarabine induction and high-dose cytarabine-based consolidation therapy in adult patients with AML
Funding Source:	Novartis
Role:	PI
ID:	CS2011-0033860RG

Date:	2009 - 2012
Title:	Proteasome/HDAC Inhibition in Leukemia/MDS; Phase 1 Trial and Correlative Studies
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	5RC2-CA148431-02

Date:	2009 - 2014
Title:	2007-0685: A Phase 2 Trial of Vorinostat in Combination with Azacitidine in Patients with Newly-Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome who are ineligible for other Leukemia Protocols. DRUG ONLY
Funding Source:	Merck and Company and Pharmion
Role:	PI
ID:	CS2008-00022766/7

Date:	2009 - 2011
Title:	DNA Methylation Pattern of Acute Lymphoid Leukemia in Adolescents and Young Adults
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 RC1 CA147225-01

Date:	2009 - 2014
Title:	2009-0129: A Phase 1 CT Study of Oral Arry-614 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
Funding Source:	Array Biopharma
Role:	PI
ID:	CS2009-00027421JW

Date:	2009 - 2013
Title:	2009-0434: A Phase II CT Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML)
Funding Source:	Novartis
Role:	PI
ID:	CS2009-00029376JW

Date:	2009 - 2014
Title:	2008-0503: Randomized controlled study of post-transplant azacitidine for prevention of disease relapse
Funding Source:	Celgene
Role:	Co-I
ID:	CS2009-00027148LG

Date:	2009 - 2011
Title:	2007-0713: Phase II Study LBH589 for Patients with Low or Intermediate-1 Myelodysplastic Syndrome
Funding Source:	Novartis
Role:	PI
ID:	CS2008-00022469MA 01

Date:	2008 - 2013
Title:	2008-0245: Phase I Study of the Histone-deacetylase Inhibitor JNJ-26481585
Funding Source:	Johnson & Johnson
Role:	PI
ID:	CS2008-00024072EB

Date:	2008 - 2010
Title:	Developmental Research Project "Histone deacetylase inhibitors in leukemia: understanding the molecular and clinical implications of their use"
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	5 P50 CA100632 07 DRP-10

Date:	2008 - 2013
Title:	2007-0883: Randomized Open-Label Phase 4 Study of Low Dose DACOGEN for Injection (Decitabine) in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (CT)
Funding Source:	MGI Pharma, Inc
Role:	PI
ID:	CS2008-00023760LG

Date:	2008 - 2013
Title:	Training Program in Biostatistics for Cancer Research
Funding Source:	NIH/NCI
Role:	Faculty mentor
ID:	5T32CA096520

Date:	2008 - 2016
Title:	2007-0848: A Phase 1 CT Dose Escalation Study of Oral SB939 when administered Thrice Weekly (every other day) for 3 weeks in a 4-week cycle in Patients with Advanced Malignancies
Funding Source:	S*BIO Pte Ltd
Role:	PI
ID:	CS2008-00022769MA

Date:	2008 - 2010
Title:	CTEP study 2005-0031 (Garcia-Manero PI of clinical trial) Phase 1 Studies of Targeted Anti-Cancer Therapies
Funding Source:	NIH/NCI
Role:	Investigator
ID:	5U01CA062461-17

Date:	2008 - 2009
Title:	Assess Potency of JNJ-26481585 in Leukemia Cell Lines and Limited Number of Ex Vivo Samples
Funding Source:	Johnson & Johnson
Role:	PI
ID:	LS2008-00022206EB

Date:	2007 - 2014
Title:	2007-0835: Phase II study of Idarubicin, Cytarabine, and Vorinostat in patients with high-risk MDS and AML
Funding Source:	Merck and Company
Role:	PI
ID:	CS2008-00022768

Date:	2007 - 2009
Title:	2007-0528: A Phase I, Open-Label, Dose-Escalation Study of CC-11006 in Subjects with Low- or Intermediate-1- Risk Myelodysplastic Syndromes (MDS)-CT
Funding Source:	Celgene
Role:	PI
ID:	CS2007-00021598RG

Date:	2007 - 2010
Title:	2007-0763: A Phase 2, Randomized, Open-Label Study of Single Agent Azaticidine (Vidaza) vs. Single Agent MGCD0103 vs. Azacitidine in Combination with MGCD0103 for the Treatment of Elderly Subjects with Newly Diagnosed Acute Myeloid Leukemia or Intermediate-2 or High-Risk Myelodysplastic Syndrome (Clinical Trial)
Funding Source:	Pharmion
Role:	PI
ID:	CS2008-00022468MA

Date:	2007 - 2010
Title:	Phase I Study of 5-Aza-2’-Deoxycytidine in Acute Lymphocytic Leukemia
Funding Source:	NIH/NCI
Role:	PI
ID:	5R21CA126457-02

Date:	2007 - 2014
Title:	2008-0165: A Prospective, Non-Interventional Multicenter Registry in Iron Overloaded Lower-Risk Myelodysplastic Patients (CT)
Funding Source:	Novartis
Role:	PI
ID:	CS2008-00022768JW

Date:	2007 - 2011
Title:	Highly Multiplexed Assays on the BioCD for Acute Lymphocytic Leukemia
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	5R21CA125336-02

Date:	2007 - 2012
Title:	Randomized Study of Combined Epigenetic Therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01-CA121104-05

Date:	2007 - 2012
Title:	2007-0405: A Phase I CT, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Funding Source:	Pharmion Corporation
Role:	PI
ID:	CS2007-00021174JW

Date:	2007 - 2009
Title:	2007-0265: A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (CT)
Funding Source:	Cyclacel, Ltd
Role:	PI
ID:	CS2007-00021062EB

Date:	2007 - 2008
Title:	Effects of the Combination of 5-azacytidine, Valproic Acid and ATRA on Malignant Cell
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	PI

Date:	2007 - 2008
Title:	Global Gene Methylation Profile of CLL Patients and its Implication in Therapy
Funding Source:	Chronic Lymphocytic Leukemia Foundation
Role:	Project Leader

Date:	2007 - 2010
Title:	2007-0201: A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Funding Source:	Merck and Company
Role:	PI
ID:	CS2007-00020389RG

Date:	2007 - 2011
Title:	2005-0895: Phase 1 Study of Low Dose 5-Aza-2-Deoxycitidine Administered Daily for 5 Days Every Other Week for Patients with Relapsed or Refractory Acute Lymphocytic Leukemia
Funding Source:	The University of Texas MD Anderson Cancer Center (Commonwealth)
Role:	PI

Date:	2007 - 2010
Title:	2006-0784: An Open-Label Dose-Escalation Study to Assess the Safety and Bioavailability of Single Oral Doses of Azacitidine in Patients with Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML, or Solid Tumors
Funding Source:	Pharmion
Role:	PI
ID:	CS2007-00018852RG

Date:	2006 - 2008
Title:	NO TITLE PROVIDED
Funding Source:	Paul Calabresi Clinical Oncology Award Program
Role:	Mentor
ID:	K12 CA088084

Date:	2006 - 2010
Title:	2006-0722: A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents
Funding Source:	Amgen
Role:	PI
ID:	CS2007-00018704

Date:	2006 - 2009
Title:	2006-0474: A Phase II Study of MGCD0103 (MG-0103) in Patients with Acute Myelogenous Leukemia/High Risk MDS who are Elderly and have Previously Untreated Disease or who are Adult and have Relapsed/Refractory
Funding Source:	Methylgene Inc
Role:	PI
ID:	CS2006-00018396JW

Date:	2006 - 2009
Title:	Prognostic and Therapeutic Implications of Aberrant DNA Methylation In Acute Lymphocytic Leukemia
Funding Source:	Leukemia and Lymphoma Society
Role:	PI
ID:	6173-07

Date:	2006 - 2007
Title:	Role of Aberrant DNA Methylation in the Pathogenesis and Prognosis of Acute Lymphocytic Leukemia
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	P50 CA100632

Date:	2006 - 2010
Title:	2005-0913: Phase 2 Study of Proteinase 3 PR1 Peptide Vaccine in MDS
Funding Source:	The Vaccine Company
Role:	PI
ID:	CS2006-00016206LE

Date:	2006 - 2010
Title:	Phase I Study of Low-Dose Azacitidine Combined with Valproic Acid in Patients with Advanced Cancers
Funding Source:	Pharmion Corporation
Role:	PI
ID:	CS2006-00015656JW

Date:	2005 - 2011
Title:	2005-0659: A phase I/II study of MGCD0103 (MG-0103) in combination with azacitidine in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia
Funding Source:	Methylgene Inc
Role:	PI
ID:	CS2005-00015410SP

Date:	2005 - 2007
Title:	Epigenetic and therapeutic profiling of chronic lymphocytic leukemia
Funding Source:	CLL Global Research Foundation
Role:	PI

Date:	2005 - 2010
Title:	2005-0417: A dose and schedule finding study of azacitidine maintenance therapy after allogeneic hematopoietic stem cell transplantation for AML and MDS
Funding Source:	Pharmion
Role:	Investigator
ID:	CS2005-14936

Date:	2005 - 2011
Title:	New Approaches to the Biology and Treatment of MDS
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	5P01CA108631-05

Date:	2005 - 2007
Title:	2004-0799: Phase I/II Study of the combination of 5-azacytidine with Valproic Acid and All-trans Retinoic acid in Patients with High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia
Funding Source:	Pharmion Corporation
Role:	PI
ID:	CS2005-00014148SP

Date:	2004 - 2009
Title:	2004-0748: A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes
Funding Source:	Methylgene
Role:	PI
ID:	CS2004-00012427SP

Date:	2004 - 2006
Title:	Phase I/II study of 5-aza-2'-deoxycytidine and valproic acid in patients with relapsed/refractory leukemias or myelodysplastic syndromes
Funding Source:	UTMDACC Institutional Research Grant
Role:	PI

Date:	2003 - 2005
Title:	Phase I/II study of 5-aza-2'-deoxycytidine and valproic acid in patients with relapsed/refractory leukemias or myelodysplastic syndromes
Funding Source:	NIH/NCI
Role:	PI
ID:	5R21CA105771

Date:	2003 - 2005
Title:	Cell Cycle Controlling Genes in Adult Acute Lymphoma
Funding Source:	NIH/NCI
Role:	PI
ID:	5 R21 CA100067

Date:	2003 - 2006
Title:	Epigenetic silencing and resistance to Imatinib mesylate in CML
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Collaborator
ID:	CM020027

Date:	2002 - 2007
Title:	NO TITLE PROVIDED
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 P50 CA100632-01

Date:	2002 - 2005
Title:	NO TITLE PROVIDED
Funding Source:	MDACC Physician-Scientist Program
Role:	PI

Date:	2001 - 2004
Title:	Studies of DNA-methylation in acute lymphocytic leukemia
Funding Source:	American Society of Clinical Oncology Career Development Award
Role:	PI

Date:	2001
Title:	NO TITLE PROVIDED
Funding Source:	Peggy Howard Memorial Fund
Role:	PI

Date:	2000 - 2001
Title:	Immunotherapy using dinitrophenyl-modified autologous cell vaccines for patients with acute and chronic myelogenous leukemia
Funding Source:	Ladies Leukemia League
Role:	PI

Date:	2000
Title:	Study of DNA-methylation in prostate cancer
Funding Source:	Association for the Cure of Prostate Cancer
Role:	PI

Date:	1998
Title:	Study of the role of the EGF receptor and GM-CSF receptor b chain receptor complex in prostate cancer
Funding Source:	Association for the Cure of Prostate Cancer
Role:	PI

Date:	1998
Title:	Non salary support to develop a peptide based immunotherapy using EGFRvIII
Funding Source:	NIH/NCI
Role:	PI

Title:	2023-0990 A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The “ELEMENT-MDS” Trial
Funding Source:	BMS
Role:	PI

Title:	Astex Strategic Alliance
Funding Source:	Astex Pharmaceuticals
Role:	PI

Title:	Therapeutic targeting of immune evasion and inflammatory pathways to prevent myelodysplastic syndrome initiation and progression
Funding Source:	Leukemia, Lymphoma Society
Role:	PI

Title:	RNA mutations in cancers: understanding the spectrum, mechanisms and translational significance
Funding Source:	NIH/NCI
Role:	Co-I

Title:	2024-0493 A Phase 3, multicenter, open label, randomized, non-comparative two arm study of ivosidenib (IVO) monotherapy and ivosidenib in combination with azacitidine (IVO+AZA) in adults with treatment naïve myelodysplastic syndromes (MDS) with an IDH1 mutation
Funding Source:	Servier
Role:	PI

Title:	2024-0454: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KER-050 in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) with Anemia
Funding Source:	Keros
Role:	PI

Patient Reviews

4.9/5 Overall Rating (243 reviews)

Understand Star Ratings

4.9/5

Listened Carefully to You

4.9/5

Explanations Easy to Understand

4.9/5

Knew Your Medical History

4.9/5

Gave Easy to Understand Instructions

4.9/5

Spent Enough Time With You

5/5

Showed Respect for You

5/5

Would Recommend Provider’s Office

4.9/5

Provider Rating 0 - 10

Comments (70)

This was my very first time I met my provider [...] My overall experience talking with him was very good.

He's a great doctor. Wish I would have met him years ago!! Good man...you can feel the good vibes coming from him. No complaints. No concerns at this time. Thanks Dr.G.

Dr. Garcia-Manero is, in my opinion, an extraordinarily qualified physician. I have known him for several years and I travel to MD Anderson because of the excellence of his medical treatment and personal connection with the patient. I rate him outstanding.

The service was fantastic. I recommend it to anybody.

I am so grateful to have care by my incredibly knowledgible and caring team at MDA. I feel that I am getting the very best care available on the planet. My deep thanks to everyone there.

1991	University of Zaragoza School of Medicine, Zaragoza, ES, Medical Doctor
1985	Colegio "Luis Vives", Palma de Mallorca, ES, Pre-Med, Bachillerato

1996-1999	Clinical Fellowship, Hematology and Medical Oncology, Thomas Jefferson University Hospital, Cardeza Foundation and Kimmel Cancer Center, Philadelphia, Pennsylvania
1993-1996	Clinical Internship and Residency, Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
1989-1991	Research Student, Royal Free Hospital School of Medicine, University of London, London
1988-1991	Honorary Intern Student, University of Zaragoza, Zaragoza

2025 - Present	Elected Member, Association of American Physicians
2024	2024 AAMDSIF Leadership in Science Award, Aplastic Anemia and MDS International Foundation
2024	Gerald P. Bodey, Sr., Distinguished Professorship Award, The University of Texas MD Anderson Cancer Center
2024	2024 Dr Ciril Rozman Award, Spanish Society of Hematology
2024	2024 Giant of Cancer Care in Leukemia, Onclive
2022	2022 Emil J Freireich Distinguished Pioneer Award, Society of Hematologic Oncology
2022	Life Time Award Leukemia Research, Society of Hematological Oncology
2020	John Mendelsohn Lifetime Achievement Award, The University of Texas MD Anderson Cancer Center
2018	The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research, The University of Texas MD Anderson Cancer Center
2017 - 2018	Best Mentor of the Year, University of Texas MD Anderson Cancer Center Fellowship Program
2015 - Present	Honorary Member, Royal Academy of Medicine of the Balearic Islands
2014	Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
2013	Irwin H. Krakoff Award for Excellence in Clinical Research, The University of Texas MD Anderson Cancer Center
2011	Robert M. Chamberlain Distinguished Mentor Award 2011 Nominee, MD Anderson Postdoctoral Association
2009	Celgene Young Investigator Award for Clinical Research in Hematology, American Society of Hematology
2009	Emil J. Frei, III Award for Excellence in Translational Research, The University of Texas MD Anderson Cancer Center
2008	Faculty Scholar Award, The University of Texas MD Anderson Cancer Center
2007	Faculty Educator of the Month, The University of Texas MD Anderson Cancer Center
2002	Physician-Scientist Program Scholar, The University of Texas MD Anderson Cancer Center
2001	Career Development Award, American Society of Clinical Oncology
1998	Winner, Oncology Research Competition, Delaware Valley Hematology Oncology Association
1994	Research Award for Clinical Trainees Program, National Institutes of Health
1991	Fellowship, European Society of Human Genetics
1990	Research Student Award, University of Zaragoza

Guillermo Garcia-Manero, M.D.

About Dr. Guillermo Garcia-Manero

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Comments (70)

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Guillermo Garcia-Manero, M.D.

About Dr. Guillermo Garcia-Manero

Present Title & Affiliation

Primary Appointment

Education & Training

Board Certifications

Experience & Service

Honors & Awards

Professional Memberships

Selected Publications

Selected Presentations & Talks

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer